NEXGEL (NXGL) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 16, 2021
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-36278
Entity Registrant Name	NEXGEL, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-4042544
Entity Address, Address Line One	2150 Cabot Blvd West
Entity Address, Address Line Two	Suite B
Entity Address, City or Town	Langhorne
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19047
City Area Code	215
Local Phone Number	702-8550
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		104,277,112
Entity Central Index Key	0001468929
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current Assets:
Cash	$ 382	$ 32
Accounts receivable, net	219	73
Inventory	226	233
Prepaid expenses and other current assets	82	25
Total current assets	909	363
Goodwill	311	311
Intangibles	40	47
Property and equipment, net	771	553
Operating lease - right of use asset	2,019	805
Other assets	60	178
Total assets	4,110	2,257
Current Liabilities:
Accounts payable	592	657
Accrued expenses and other current liabilities	70	90
Deferred Revenue	0	38
Convertible notes payable	511	59
Current portion of debt	18	10
Note payable - PPP	127	147
Warrant liability	245	123
Operating lease liability, current portion	207	207
Total current liabilities	1,770	1,331
Long-Term Liabilities:
Notes payable	253	256
Lease liability, long term	1,818	598
Total long-term liabilities	2,071	854
Total liabilities	3,841	2,185
Commitments and Contingencies
Preferred Stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, par value $0.001 per share, 750,000,000 shares authorized; 104,277,612 and 99,331,279 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	104	99
Additional paid-in capital	4,197	2,474
Accumulated deficit	(4,032)	(2,502)
Total stockholders' equity	269	71
Total liabilities and stockholders' equity	$ 4,110	$ 2,256

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
CONDENSED BALANCE SHEETS
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	104,277,112	99,331,279
Common Stock, Shares, Outstanding	104,277,112	99,331,279

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
CONDENSED STATEMENTS OF OPERATIONS
Revenues, net	$ 417,000	$ 91,000	$ 683,000	$ 331,000
Cost of revenues	413,000	176,000	722,000	349,000
Gross (loss)/profit	4,000	(85,000)	(39,000)	(18,000)
Operating expenses
Selling, general and administrative	557,000	455,000	1,034,000	1,031,000
Total operating expenses	557,000	455,000	1,034,000	1,031,000
Loss from operations	(553,000)	(540,000)	(1,073,000)	(1,049,000)
Other income (expense)
Interest expense	(370,000)	0	(518,000)	(1,000)
Loss on debt extinguishment	0	0	(25,000)	0
Debt discount costs	(52,000)	0	(68,000)	0
Forgiveness of debt	147,000	0	147,000	0
Other income	0	8,000	0	8,000
Change in fair value of warrant liability	2,000	2,000	8,000	4,000
Total other income (expense)	(273,000)	10,000	(456,000)	11,000
Loss before income taxes	(826,000)	(530,000)	(1,529,000)	(1,038,000)
Income tax expense	0	0	0	0
Net loss	$ (826,000)	$ (530,000)	$ (1,529,000)	$ (1,038,000)
Net loss per common share - basic	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.01)
Net loss per common share - diluted	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.01)
Weighted average shares used in computing net loss per common share - basic	102,894,279	76,338,541	102,156,565	70,445,816
Weighted average shares used in computing net loss per common share - diluted	102,894,279	76,338,541	102,156,565	70,445,816

CONDENSED STATEMENTS OF STOCKHO

CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 57,000	$ 561,000	$ (238,000)	$ 380,000
Balance (in Shares) at Dec. 31, 2019	57,505,208
Share-based compensation	$ 0	64,000	0	64,000
Issuances of common stock, net of issuance costs	$ 16,000	604,000	0	620,000
Issuances of common stock, net of issuance costs (in shares)	15,500,000
Net loss	$ 0	0	(508,000)	(508,000)
Balance at Mar. 31, 2020	$ 73,000	1,229,000	(746,000)	556,000
Balance (in Shares) at Mar. 31, 2020	73,005,208
Balance at Dec. 31, 2019	$ 57,000	561,000	(238,000)	380,000
Balance (in Shares) at Dec. 31, 2019	57,505,208
Net loss				(1,038,000)
Balance at Jun. 30, 2020	$ 82,000	1,635,000	(1,276,000)	441,000
Balance (in Shares) at Jun. 30, 2020	82,380,208
Balance at Mar. 31, 2020	$ 73,000	1,229,000	(746,000)	556,000
Balance (in Shares) at Mar. 31, 2020	73,005,208
Share-based compensation	$ 0	40,000	0	40,000
Issuances of common stock, net of issuance costs	$ 9,000	366,000	0	375,000
Issuances of common stock, net of issuance costs (in shares)	9,375,000
Net loss	$ 0	0	(530,000)	(530,000)
Balance at Jun. 30, 2020	$ 82,000	1,635,000	(1,276,000)	441,000
Balance (in Shares) at Jun. 30, 2020	82,380,208
Balance at Dec. 31, 2020	$ 99,000	2,474,000	(2,502,000)	71,000
Balance (in Shares) at Dec. 31, 2020	99,331,779
Share-based compensation		69,000		69,000
Restricted stock vesting		21,000		21,000
Restricted stock vesting (in shares)	0
Issuances of common stock, net of issuance costs	$ 4,000	281,000		285,000
Issuances of common stock, net of issuance costs (in shares)	3,563,000
Warrants issued for debt issuance	$ 0	(18,000)	0	(18,000)
Beneficial conversion and warrant features of convertible debt	0	1,276,000	0	1,276,000
Net loss			(704,000)	(704,000)
Balance at Mar. 31, 2021	$ 103,000	4,103,000	(3,206,000)	1,000,000
Balance (in Shares) at Mar. 31, 2021	102,894,779
Balance at Dec. 31, 2020	$ 99,000	2,474,000	(2,502,000)	71,000
Balance (in Shares) at Dec. 31, 2020	99,331,779
Net loss				(1,529,000)
Balance at Jun. 30, 2021	$ 104,000	4,197,000	(4,032,000)	269,000
Balance (in Shares) at Jun. 30, 2021	104,277,112
Balance at Mar. 31, 2021	$ 103,000	4,103,000	(3,206,000)	1,000,000
Balance (in Shares) at Mar. 31, 2021	102,894,779
Share-based compensation		74,000		74,000
Restricted stock vesting	$ 1,000	20,000		21,000
Restricted stock vesting (in shares)	1,383,333
Net loss			(826,000)	(826,000)
Balance at Jun. 30, 2021	$ 104,000	$ 4,197,000	$ (4,032,000)	$ 269,000
Balance (in Shares) at Jun. 30, 2021	104,277,112

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating Activities
Net loss	$ (1,529)	$ (1,038)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	56	21
Share-based compensation	185	104
Change in fair value of warrant liability	(8)	(4)
Amortization of deferred financing costs	528	0
Loss on debt extinguishment	24	0
Forgiveness of debt	(148)	0
Beneficial conversion feature in excess of face value	51	0
Change in ROU asset and operating lease liability	6	0
Changes in operating assets and liabilities:
Accounts receivable	(146)	5
Inventory	7	(34)
Prepaid expenses and other assets	61	19
Accounts payable	(67)	(106)
Accrued expenses and other liabilities	(15)	53
Deferred revenue	(38)	0
Net Cash Used in Operating Activities	(1,033)	(980)
Investing Activities
Capital expenditures	(267)	(76)
Net Cash Used in Investing Activities	(267)	(76)
Financing Activities
Issuance of common stock, net of issuance costs	285	620
Proceeds from notes payable	15	408
Principle payment of notes payable	(15)	0
Proceeds from notes payable (PPP)	128	0
Proceeds from convertible notes	1,337	0
Principal payment on convertible notes	(100)	0
Net Cash Provided by Financing Activities	1,650	1,028
Net Increase in Cash	350	(28)
Cash - Beginning of period	32	261
Cash - End of period	382	233
Cash paid during the year for:
Interest	0	0
Taxes	0	0
Supplemental Non-cash Investing and Financing activities
Fair value of beneficial conversion and warrant features of Convertible Notes Payable	1,276	0
Original issue discounts recognized on Convertible Notes Payable	343	0
Warrants issued for debt and equity financing costs	130	0
Common Shares issued for acquisition	0	375
Inventory acquired from acquisition	0	21
Accounts payable assumed from acquisition	$ 0	$ 13

Description of Business, the Sp

Description of Business, the Spin-off and Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Description of Business, the Spin-off and Basis of Presentation
Description of Business, the Spin-off and Basis of Presentation	1. Description of Business, the Spin-off and Basis of Presentation Description of Business NexGel, Inc. (the “Company” or “NexGel”) manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The Company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company has historically served as a contract manufacturer supplying its gels to third parties who incorporate them into their own products. NexGel was previously known as AquaMed Technologies, Inc. (“AquaMed”) before changing its name to NexGel, Inc. on November 14, 2019. The Company is implementing a new strategy to become a consumer products business focused on proprietary branded products and white label opportunities. The Spin-Off On June 21, 2019, NexGel became an independent company through the pro rata distribution (“Spin-Off”) by Adynxx, Inc. (“Adynxx” and the “Parent”) in connection with the closing of a reverse merger between Adynxx, Inc. and Alliqua BioMedical, Inc., (“Adynxx”) of NexGel’s common stock for common stock of Parent. Adynxx, Inc. was previously known as Alliqua BioMedical, Inc. and subsequently changed its name to Adynxx, Inc. on May 3, 2019. The terms and conditions of the Spin-Off provided that each record holder of Parent stock as of April 22, 2019, received one share of NexGel common stock in book-entry form and resulted in the distribution of 5,005,211 shares of common stock of NexGel. Following the distribution (“Capitalization”), all existing operations were distributed to NexGel with the exception of a corporate lease for property in Yardley, Pennsylvania which was retained by Adynxx, Inc. Pursuant to the Spin-Off and in exchange for the 5,005,211 shares of common stock,NexGel assumed the following net assets and liabilities from Parent as of June 21, 2019 ($ in thousands): ​ ​ ​ ​ ​ Assets: ​ ​ Cash ​ $ 186 Accounts receivable, net ​ 72 Inventory, net ​ 140 Prepaid expenses and other current assets ​ 101 Property and equipment, net ​ 155 Operating lease - right of use asset ​ 976 Other assets ​ 178 Total assets ​ 1,808 ​ ​ ​ ​ Liabilities: ​ ​ ​ Accounts payable ​ (496) Accrued expenses and other current liabilities ​ (395) Operating lease liability - current ​ (207) Long-term operating lease liability ​ (769) Total liabilities ​ (1,867) ​ ​ ​ ​ Net liabilities assumed in Spin-Off on June 21, 2019 ​ $ (59) ​ Basis of Presentation The balance sheet as of June 30, 2021 and December 31, 2020 and the statements of operations, stockholders’ equity, and cash flows for the six months ended June 30, 2021 consists of the balances of NexGel as prepared on a stand-alone basis. Prior to the separation, these financial statements were derived from the consolidated financial statements and accounting records of Adynxx, Inc. Prior to the Spin-Off, Adynxx used a centralized approach to cash management and financing its operations, including the operations of the Company. Accordingly, none of the cash of Adynxx have been attributed to the Company in the financial statements. Transactions between Adynxx and the Company were accounted for through Parent’s Net Investment. The expenses, including executive compensation, have been allocated by management based either on specific attribution of those expenses or, where necessary and appropriate, based on management’s best estimate of an appropriate proportional allocation. These interim condensed financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the "SEC"), which permit reduced disclosure for interim periods. The condensed balance sheet as of June 30, 2021 was derived from audited financial statements for the fiscal year then ended, but does not include all necessary disclosures required by generally accepted accounting principles in the United States of America ("GAAP") with respect to annual financial statements. In the opinion of management, the condensed financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of June 30, 2021 and results of operations and cash flows for the three months ended June 30, 2021 and 2020. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto in the Company’s year-end financial statements for the years ended December 31, 2020 and 2019, which are included in the Company’s Form 10-K filed with SEC on June 30, 2021. Results for interim periods are not necessarily indicative of the results to be expected for a full fiscal year or for any future period. Significant Accounting Policies and Estimates The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes. These estimates and assumptions include allowance for doubtful accounts, inventory reserves, deferred taxes, share-based compensation and related valuation allowances and fair value of long-lived assets. Actual results could differ from the estimates. Accounts receivable, net Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable and records a provision to the allowance for doubtful accounts based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded in selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for doubtful accounts was $4 thousand as of June 30, 2021 and $1 thousand as of December 31, 2020. Inventory Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. The Company evaluates inventories for excess quantities, obsolescence or shelf-life expiration. This evaluation includes an analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf-life expiration dates for products. These factors determine when, and if, the Company adjusts the carrying value of inventory to estimated net realizable value. The balance is made up of raw materials of $189 thousand and $190 thousand, work-in-progress of $23 thousand and $22 thousand, and finished goods of $14 thousand and $21 thousand on June 30, 2021 and December 31, 2020, respectively. Property and equipment, net Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. Repairs and maintenance costs are expensed as incurred. Management periodically assesses the estimated useful life over which assets are depreciated or amortized. If the analysis warrants a change in the estimated useful life of property and equipment, management will reduce the estimated useful life and depreciate or amortize the carrying value prospectively over the shorter remaining useful life. The carrying amounts of assets sold or retired and the related accumulated depreciation are eliminated in the period of disposal and the resulting gains and losses are included in the results of operations during the same period. Goodwill and Intangible Assets In applying the acquisition method of accounting, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Identifiable intangible assets are initially valued at fair value using generally accepted valuation methods appropriate for the type of intangible asset. Identifiable intangible assets with definite lives are amortized over their estimated useful lives and are reviewed for impairment if indicators of impairment arise. Intangible assets with indefinite lives are tested for impairment within one year of acquisitions or annually as of December 1, and whenever indicators of impairment exist. The fair value of intangible assets is compared with their carrying values, and an impairment loss would be recognized for the amount by which a carrying amount exceeds its fair value. Acquired identifiable intangible assets are amortized over the following periods: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Expected Life Acquired intangible Asset Amortization Basis (years) Technology-Related Straight-line basis 3 Marketing-Related Straight-line basis 4 ​ Impairment of Long-Lived Assets We review the recoverability of our long-lived assets, including equipment and right-of-use assets, when events or changes in circumstances occur that indicate that the carrying value of the asset, or asset group, may not be recoverable. Events or circumstances that might cause management to perform impairment testing include, but are not limited to, significant underperformance relative to historical or projected future operating results of the asset or asset group, significant changes in the manner or use of assets or the strategy for our overall business; and significant negative industry or economic trends. If indicators of potential impairment are present, management performs a recoverability test and, if necessary, records an impairment loss. If the total estimated future undiscounted cash flows to be generated from the use and ultimate disposition of an asset or asset group is less than its carrying value, an impairment loss is recorded in the Company’s results of operations, measured as the amount required to reduce the carrying value to fair value. Fair value is determined in accordance with the best available information per the hierarchy described under Fair Value Measurements Prepaid expenses and other current assets Prepaid expenses and other current assets is recorded at historical cost and is primarily made up of $26 thousand and $16 thousand of prepaid insurance, and $56 thousand and $9 thousand general prepaid expenses and other current assets in the period ended June 30, 2021 and December 31, 2020, respectively. Other Assets Other Assets is recorded at historical costs, and as of June 30, 2021 and December 31, 2020, the balance is entirely made up of spare parts for manufacturing equipment. Other assets are stated at cost and are not subject to depreciation, until such time that they are placed into service and the part that is being replaced is disposed. Fair value measurements The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: Level 1 Level 2 Level 3 The Company considers the carrying amounts of its financial instruments (cash, accounts receivable and accounts payable) in the balance sheet to approximate fair value because of the short-term or highly liquid nature of these financial instruments. Warrant Liability Warrants to purchase common stock were issued in connection with equity financing raises, which occurred on March 11, 2021, February 3, 2021, December 24, 2020, March 18, 2020, September 10, 2019 and November 6, 2019. The fair values of the warrants are estimated as of the date of issuance and again at each period end using a Black-Scholes option valuation model. At issuance, the fair value of the warrant is recognized as an equity issuance cost within additional paid-in-capital. Fair value adjustments to the warrant liability are recognized in other income (expense) in the statements of operations. Revenue recognition On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers The Company recognizes revenue predominately from three types of revenue, contract manufacturing, custom and white label manufacturing and proprietary branded products. Revenue from contract manufacturing is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. The Company’s customers consist of other life sciences companies and revenues are concentrated in the United States. Payment terms vary by the type and location of customer and may differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 60 days from date of shipment. Estimates for product returns, allowances and discounts are recorded as a reduction of revenue and are established at the time of sale. Returns are estimated through a comparison of historical return data and are determined for each product and adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have not been material. Amounts accrued for sales allowances and discounts are based on estimates of amounts that are expected to be claimed on the related sales and are based on historical data. Payments for allowances and discounts have historically been immaterial. Disaggregated revenue by sales type: ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ June 30, ​ 2021 2020 Contract manufacturing ​ $ 379 ​ $ 331 Custom and white label finished goods manufacturing ​ 194 ​ — Nexgel branded consumer products ​ 110 ​ — ​ ​ ​ ​ ​ ​ ​ Total ​ $ 683 ​ $ 331 ​ As of June 30, 2021, the Company did not have any contract assets or contract liabilities from contracts with customers. As of June 30, 2021, there were no remaining performance obligations that the Company had not satisfied. Share-based compensation On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan (the “2019 Plan”). The 2019 Plan provides for the granting of incentive stock options, nonqualified stock options, restricted stock, stock appreciation rights (“SARs”), restricted stock units, performance awards, dividend equivalent rights and other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash, shares of common stock of the Company or a combination of cash and shares of common stock of the Company. The Company initial reserved a total of 2,000,000 shares of the Company’s common stock for awards under the 2019 Plan. Effective as of May 26, 2020 and May 3, 2021, respectively, the Board approved an increase of the number of authorized shares of common stock reserved under the 2019 Plan from 2,000,000 shares of common stock to 17,000,000 shares of common stock and from 17,000,000 shares of common stock to 20,000,000 shares of common stock, all of which may be delivered pursuant to incentive stock options. Subject to adjustments pursuant to the 2019 Plan, the maximum number of shares of common stock with respect to which stock options or SARs may The Company’s 2019 Long-Term Incentive Plan provides certain employees, contractors and outside directors with share-based compensation in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. Forfeitures are accounted for when they occur. In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-07, Compensation - Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting Compensation - Stock Compensation Income taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. Segment reporting The Company operates in one business segment as a contract manufacturer of aqueous polymer hydrogels. As a result, the Company’s operations are a single reportable segment, which is consistent with the Company’s internal management reporting. Comprehensive loss Comprehensive loss consists of net loss and changes in equity during a period from transactions and other equity and circumstances generated from non-owner sources. The Company’s net loss equals comprehensive loss for all periods presented, Recently Adopted Accounting Standards In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) Recently Issued Accounting Standards From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. Fair Value Measurement—Disclosure Framework In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2021
Going Concern
Going Concern	2. Going Concern As of June 30, 2021, the Company had a cash balance of $382,000. For the six months ended June 30, 2021, the Company incurred a net loss of $1,529,000 and had a net usage of cash in operating activities of $1.03 million. In addition, the Company had a working capital deficit of $860,000 as of June 30, 2021. The Company expects to continue incurring losses for the foreseeable future and will need to raise additional capital to support ongoing operations. The ability of the Company to continue to operate as a going concern is dependent upon its ability to raise additional capital and to ultimately achieve profitable operations. Management is evaluating various options to raise capital to fund the Company’s working capital requirements through equity offerings. There can be no assurances, however, that management will be able to obtain sufficient additional funds when needed, or that such funds, if available, will be obtained on terms satisfactory to the Company. These factors raise substantial doubt as to the Company’s ability to continue as a going concern. The condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2021
Net Loss Per Common Share
Net Loss Per Common Share	3. Net Loss Per Common Share Basic loss per share data is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share data is computed using the weighted-average number of common and dilutive common-equivalent shares outstanding during the period. Dilutive common-equivalent shares consist of shares that would be issued upon the exercise of stock options and other common stock equivalents, computed using the treasury stock method. The number of shares that may be issued for share-based payment awards under the Company’s 2019 Long-Term Incentive Plan are excluded from the calculation of weighted average dilutive common shares for the three months ended June 30, 2021 and 2020, to the extent they are issued and outstanding, because their effect would be anti-dilutive.

Acquisition

Acquisition	6 Months Ended
	Jun. 30, 2021
Acquisition
Acquisition	4. Acquisition On May 29, 2020, the Company entered into a Membership Interest Purchase Agreement (the "Purchase Agreement") whereby the Company purchased all of the outstanding equity securities of Sport Defense LLC, a Delaware limited liability company ("Sports Defense"), from the members of Sport Defense (the "Sellers"). Subsequent to the Closing Date, Sport Defense is a wholly-owned subsidiary of the Company. Sport Defense is a marketing and distribution company that leverages the unique benefits of ultra-gentle, high-water content hydrogels, manufactured by the Company, to build brands that treat various ailments of the skin caused by athletic training, such as blisters, turf burns, scrapes and skin irritations. Under the terms of the Purchase Agreement, the purchase price paid to the Sellers was an aggregate of $375 thousand (the "Purchase Price") which was paid by the Company through the issuance of an aggregate of 9,375,000 shares of the Company's common stock, par value $0.001 (the "Shares"), which equates to a per share purchase price of $0.04. The Shares are "restricted securities" as such term is defined by Rule 144 promulgated under the Securities Act of 1933, as amended. Adam Levy, the Company's Chief Executive Officer and Chief Financial Officer, and Nachum Stein, a member of the Company's Board of Directors (the "Board"), were each members of Sport Defense and part of the Sellers. Mr. Levy received 1,546,875 of the Shares and Mr. Stein received 3,187,500 of the Shares. Due to the potential conflict of interest that existed because of Messrs. Levy and Stein's partial ownership of Sport Defense, the Board obtained an independent investment bank to prepare a valuation report with respect to Sport Defense. This valuation report supported the Purchase Price. Also, Mr. Stein recused himself from the vote of the Board regarding the approval to purchase Sport Defense. The Purchase Agreement and the Sport Defense acquisition were not subject to approval by the shareholders of the Company. The Purchase Agreement contained minimal representations and warranties regarding Sport Defense and certain limited representations and warranties regarding the Company and the Sellers. The provisional fair value of the purchase consideration issued to the Seller was allocated to the net tangible assets acquired. The Company accounted for the Sports Defense acquisition as the purchase of a business under GAAP under the acquisition method of accounting, and the assets and liabilities acquired were recorded as of the acquisition date, at their respective fair values and consolidated with those of the Company. The fair value of the net assets acquired was approximately $375 thousand. The excess of the aggregate fair value of the net tangible assets has been allocated to goodwill. The Company is currently in the process of completing the preliminary purchase price allocation as an acquisition of certain assets. The final purchase price allocation for Sports Defense's will be included in the Company's financial statements in future periods. The table below shows preliminary analysis for the Sports Defense acquisition: ​ ​ ​ ​ ​ Provisional Purchase Consideration at preliminary fair value: ​ Purchase price ​ $ 375 Amount of consideration ​ $ 375 ​ ​ ​ ​ Assets acquired and liabilities assumed at preliminary fair value ​ Inventories ​ 21 Product/Technology related intangibles ​ ​ 31 Marketing related intangibles ​ ​ 8 Customer related intangibles ​ ​ 17 Accounts payable and accrued expenses ​ (13) Other liabilities ​ — Net tangible assets acquired ​ $ 64 ​ ​ ​ ​ Total net assets acquired ​ $ 64 Consideration paid ​ 375 Preliminary goodwill ​ $ 311 ​ The unaudited pro-forma results of operations are presented for information purposes only. The unaudited pro-forma results of operations are not intended to present actual results that would have been attained had the Sports Defense acquisition been completed as of January 1, 2019 or to project potential operating results as of any future date or for any future periods. ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months Ended ​ ​ June 30, ​ 2021 2020 Revenues, net ​ $ 683 ​ $ 348 Net loss allocable to common shareholders ​ $ (1,529) ​ $ (1,029) Net loss per share ​ $ (0.01) ​ $ (0.01) Weighted average number of shares outstanding ​ 102,156,565 ​ 78,258,316 ​

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases
Leases	5. Leases The Company has one operating lease for a commercial manufacturing facility and administrative offices located in Langhorne, Pennsylvania that expired in January 2026. On April 14, 2021, the Company extended the term of the lease for an additional five years commencing on February 1, 2026 and continuing through January 31, 2031. The right-of-use asset and lease liability from this operating lease were recognized in the opening balance sheet as of January 1, 2019 and are based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rate. The following table presents information about the amount and timing of the liability arising from the Company’s operating lease as of June 30, 2021 ($ in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Operating ​ ​ ​ Lease ​ Maturity of Lease Liability ​ Liability ​ 2021 (remainder of year) $ 104 ​ 2022 ​ 207 ​ 2023 ​ 207 ​ 2024 ​ ​ 207 ​ 2025 ​ 207 ​ Thereafter ​ ​ 1,428 ​ Total undiscounted operating lease payments ​ $ 2,360 ​ Less: Imputed interest ​ (335) ​ Present value of operating lease liability ​ $ 2,025 ​ Weighted average remaining lease term ​ ​ 9.6 years ​ Weighted average discount rate ​ ​ 3.0 % ​ Total operating lease expense for the three months ended June 30, 2021 and 2020 was $103 thousand and $6 thousand related to the lease extension, and is recorded in cost of goods sold and selling, general and administrative expenses on the statement of operations under Accounting Standards Codification Topic 840, Leases. Supplemental cash flows information related to leases was as follows ($ in thousands): ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2021 ​ Cash paid for amounts included in the measurement of lease liability: ​ ​ ​ ​ Operating cash flows from operating lease ​ $ 109 ​ Change in right-of-use asset/liability due to lease amendments ​ $ 1,275 ​ ​

Inventory

Inventory	6 Months Ended
	Jun. 30, 2021
Inventory
Inventory	6. Inventory Inventory consists of the following ($ in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 Raw materials ​ $ 189 ​ $ 190 Work-in-progress ​ ​ 23 ​ ​ 22 Finished goods ​ ​ 14 ​ ​ 21 ​ ​ ​ 226 ​ ​ 233 Less: Inventory reserve for excess and slow moving inventory ​ — ​ — Total ​ $ 226 ​ $ 233 ​ As a contract manufacturer, the Company builds its products based on customer orders and immediately ships the products upon completion of the production process.

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2021
Property and Equipment, Net
Property and Equipment, Net	7. Property and Equipment, Net Property and equipment consist of the following ($ in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Useful Life June 30, December 31, ​ ​ (Years) ​ 2021 ​ 2020 Machinery and equipment ​ 3 - 10 ​ $ 940 ​ $ 2,894 Office furniture and equipment 3 - 10 ​ 49 ​ 49 Leasehold improvements 6 ​ 228 ​ 228 Construction in progress ​ N/A ​ ​ — ​ ​ 461 ​ ​ ​ 1,217 ​ 3,632 Less: accumulated depreciation and amortization ​ ​ (446) ​ (3,079) Property and equipment, net $ 771 $ 553 ​ Depreciation and amortization expense for the six months ended June 30, 2021 and 2020 was $49 thousand and $21 thousand, respectively.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2021
Intangible Assets
Intangible Assets	8. Intangible Assets The following provides a breakdown of identifiable intangible assets as of June 30, 2021 and December 31, 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 Product/Technology Related ​ ​ ​ ​ Identifiable intangible assets, gross ​ $ 31 ​ $ 31 Accumulated amortization ​ (11) ​ ​ (6) Product/Technology Related identifiable intangible assets, net ​ 20 ​ ​ 25 Marketing Related ​ ​ ​ ​ Customer related intangible asset, gross ​ ​ 17 ​ ​ 17 Tradename related intangible asset, gross ​ 7 ​ ​ 7 Accumulated amortization ​ (4) ​ ​ (2) Marketing related identifiable intangible assets, net ​ 20 ​ ​ 22 Total Identifiable intangible assets, net ​ $ 40 ​ $ 47 ​ In connection with the acquisitions of Sports Defense, the Company identified intangible assets of $55 thousand representing technology related and customer related intangibles. These assets are being amortized on a straight-line basis over their weighted average estimated useful life of 4.7 years and amortization expense amounted to $7 thousand for the six months ended June 30, 2021. As of June 30, 2021, the estimated annual amortization expense for each of the next five fiscal years is as follows: ​ ​ ​ ​ ​ 2021 (remainder of year) $ 7 2022 ​ 14 2023 ​ 8 2024 ​ 3 2025 ​ 2 Thereafter ​ ​ 6 Total ​ $ 40 ​

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2021
Accrued Expenses and Other Current Liabilities
Accrued Expenses and Other Current Liabilities	9. Accrued Expenses and Other Current Liabilities ​ Accrued expenses and other current liabilities consist of the following ($ in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 Salaries, benefits and incentive compensation ​ $ 47 ​ $ 43 Other ​ 23 ​ 47 Total accrued expenses and other current liabilities ​ $ 70 ​ $ 90 ​

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2021
Common Stock
Common Stock	10. Common Stock Share issuances On September 10, 2019, the Company entered into a Stock Purchase Agreement to issue and sell shares of the Company’s common stock, par value $0.001 per share, in a private placement offering to accredited investors for an aggregate of up to $175 on the initial closing date, and an aggregate of up to $575 of shares of common stock on a subsequent closing date at a price per share equal to $0.053525. On September 10, 2019, certain accredited investors purchased 3,269,500 shares of the Company’s common stock that resulted in cash proceeds of $175 thousand. For their commitment to invest the $175 thousand, the two shareholders who invested in the September 10, 2019 private placement each became a member of the Company’s Board of Directors and gained control of the Company. Their investments carried full ratchet protection on the purchase price per share of $0.053525 because the actual price of the shares in the September 10, 2019 private placement was undetermined at that time. The final price per share of the September 10, 2019 private placement, which was governed by a term sheet dated August 27, 2019, was ultimately determined to be $0.014. On November 6, 2019 and pursuant to the Stock Purchase Agreement, the Company issued an additional 39,999,998 shares of its common stock, par value $0.001 per share, in a private placement offering to accredited investors valued at $0.014 per share and raised $560 thousand. Proceeds from this offering are expected to be used for working capital and general business operations. Upon the completion of the secondary offering on November 6, 2019 that provided for the settlement of the ratchet protection, there was a reclassification from Additional paid-in capital to Common stock for the par value of the 9,230,500 additional shares that were issued to the two shareholders who invested in the September 10, 2019 private placement. Issuance costs related to the September 10, 2019 and November 6, 2019 private placements totaled $5 dollars in legal fees and $56 thousand related to warrants issued as an equity issuance cost. See Note 15- Warrant Liability. From January 1, 2021 through March 31, 2021, the Company entered into Securities Purchase Agreements with certain accredited investors whereby we sold 3,563,000 shares of our common stock at a price per share equal to $0.08 for an aggregate purchase price of $285,000. From February 6, 2020 through March 20, 2020, the Company entered into Securities Purchase Agreements with certain accredited investors whereby we sold 15,500,000 shares of our common stock at a price per share equal to $0.04 for an aggregate purchase price of $620,000. Proceeds from this offering are expected to be used for working capital, new product development and testing, and general business operations. The placement agent for the private placement and is entitled to receive a total fee equal to 6% of the total gross proceeds and warrants to purchase the number of shares of Common Stock equal to 10% of the number of shares of Common Stock issued to the Investors, for such services rendered. The warrants are exercisable for 3 years at an exercise price equal to $0.04. As of June 30, 2021, the Company has reserved common stock for issuance in relation to the following: ​ ​ ​ ​ Share-based compensation plan 17,000,000 Warrants to purchase common stock 19,827,500 ​ On February 10, 2020, a majority of our stockholders through a written consent approved the following: (i) an amendment to our Restated Certificate of Incorporation which will increase the number of authorized shares of Common Stock from 100,000,000 shares of Common Stock to 3,000,000,000 shares of Common Stock and (ii) an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of our Common Stock by a ratio of not less than one-for-thirty one-for-one hundred ​ On June 22, 2021, a majority of our stockholders through a written consent approved an amendment to our Restated Certificate of Incorporation to decrease the number of authorized shares of Common Stock from 3,000,000,000 shares of Common Stock to 750,000,000 shares of Common Stock. On August 2, 2021, the Company filed the amendment to its certificate of incorporation to decrease the number of the Company’s authorized shares of common stock from 3,000,000,000 shares of common stock to 750,000,000 shares of common stock. For more information on this amendments, please see the Company’s Definitive Information Statement on Schedule 14C filed with the SEC on July 12, 2021.

Concentrations of Risk

Concentrations of Risk	6 Months Ended
	Jun. 30, 2021
Concentrations of Risk
Concentrations of Risk	11. Concentrations of Risk The Company’s revenues are concentrated in a small group of customers with some individually having more than 10%of total revenues. Revenues from three customers that exceeded 10% of total revenues for the period ended June 30, 2021 were 28%, 24%, and 16%. The accounts receivable from the top three customers were 13%, 0%, and 44% as well as 25% from one other customer of the total accounts receivable as of June 30, 2021. Revenues from three customers that exceeded 10% of total revenues for the period ended June 30, 2020 were 23%,27% and 39%. The accounts receivable from the four customers were 59%, 13%, 12%, and 11% as of June 30, 2020. The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash. Cash balances are maintained principally at major U.S. financial institutions and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. From time to time, cash balances may exceed the FDIC insurance limit. The Company has not experienced any credit losses associated with its cash balances in the past. ​

Share-based Compensation

Share-based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Compensation
Share-based Compensation	12. Share-based Compensation On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan (the “2019 Plan”). The 2019 Plan provides for the granting of incentive stock options, nonqualified stock options, restricted stock, stock appreciation rights (“SARs”), restricted stock units, performance awards, dividend equivalent rights and other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash, shares of common stock of the Company or a combination of cash and shares of common stock of the Company. The Company initially reserved a total of 2,000,000 shares of the Company’s common stock for awards under the 2019 Plan. Effective as of May 26, 2020 and May 3, 2021, respectively, the Board approved an increase of the number of authorized shares of common stock reserved under the 2019 Plan from 2,000,000 shares of common stock to 17,000,000 shares of common stock and from 17,000,000 shares of common stock to 20,000,000 shares of common stock, all of which may be delivered pursuant to incentive stock options., all of which may be delivered pursuant to incentive stock options. Subject to adjustments pursuant to the 2019 Plan, the maximum number of shares of common stock with respect to which stock options or SARs may be granted to an executive officer during any calendar year is 500,000 shares of common stock. Incentive stock options On March 8, 2021, the Company granted Dr. Jerome Zeldis, a member of the Company Board, an option to purchase up to 666,667 shares of the Company’s common stock at a per share exercise price of $0.06 under the Company’s 2019 Long-Term Incentive Plan. This option award fully vested as of the date of grant. On March 8, 2021, the Company appointed Steven Glassman to the Board of Directors to serve for a term expiring at the next annual meeting of stockholders or until his successor is duly elected and qualified. On March 8, 2021 and in consideration for his appointment to the board of directors, the Company granted Mr. Glassman an option to purchase up to 500,000 shares of common stock at a per share exercise price of $0.08 under the Company’s 2019 Long-Term Incentive Plan. This option award fully vested as of the date of grant. On January 15, 2021, the Company awarded a contractor options to purchase an aggregate of 500,000 shares of the Company’s common stock at a per share exercise price of $0.06 under the Company’s 2019 Long-Term Incentive Plan. This option award fully vested 20% as of the date of grant and the remaining 80% in November 2022. In May 2020 and July 2020, pursuant to the terms of the 2019 Plan, the Company awarded options to purchase an aggregate of 5,325,000 shares of common stock to two of its employees and one contractor. Pursuant to the terms of the option agreements, 325,000 of the options vested on the date of grant, and of the 5,000,000 options, 10% of such options vested on the date of grant, and the remaining of such options will vest upon meeting established criteria. The term of the options is ten years. On February 17, 2020, the Company granted certain equity awards to the members of the Company's Board of Director with the following terms: each of Messrs. Stefansky and Stein received two annual awards of stock options equal to $40,000 of the Company's common stock, granted under the Company 2019 Long-Term Incentive Plan (the "Incentive Plan"), with (i) the first grant being the right to purchase up to 2,857,141 shares of the Company's common stock at a per share exercise price of $0.014 with one-half one-half one-fourth The following table contains information about the 2019 Plan as of June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ Awards ​ Awards ​ ​ Reserved for ​ ​ ​ Available for ​ ​ Issuance ​ Awards Issued ​ Grant 2019 Plan 17,000,000 14,705,949 2,294,051 ​ The following table summarizes the Company’s incentive stock option activity and related information for the period ended December 31, 2020 and for the period ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average ​ ​ Number of ​ Exercise ​ Contractual ​ ​ Options ​ Price ​ Term in Years Outstanding at January 1, 2020 1,000,000 $ 0.053525 9.6 Granted 12,705,949 ​ $ 0.0291 10.0 Exercised — ​ — — Forfeited — ​ — — Cancelled — ​ — — Expired — ​ — — Outstanding at December 31, 2020 ​ 13,705,949 ​ $ 0.027736 ​ 9.32 ​ ​ ​ ​ ​ ​ ​ ​ Granted ​ 1,666,667 ​ $ 0.08 ​ 10.0 Exercised ​ — ​ ​ — ​ — Forfeited ​ — ​ ​ — ​ — Cancelled ​ — ​ ​ — ​ — Expired ​ — ​ ​ — ​ — Outstanding at June 30, 2021 15,372,616 ​ $ 0.034889 8.91 Exercisable at June 30, 2021 ​ 9,105,949 ​ $ 0.025441 ​ 8.75 ​ As of June 30, 2021, vested outstanding stock options had $988 thousand intrinsic value as the exercise price is greater than the estimated fair value of the underlying common stock. As of June 30, 2021, there was approximately $75 thousand of total unrecognized share-based compensation related to unvested stock options, which the Company expects to recognize over the next 12 months. The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period. The following assumptions were used to calculate share-based compensation expense for six months ended June 30, 2021: ​ ​ ​ ​ ​ Volatility 171.12%- 172.19 % Risk-free interest rate ​ 0.46% - 0.86 % Dividend yield 0.0 % Expected term 5.0 – 5.25 years ​ The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Accordingly, the Company has elected to use the “simplified method” to estimate the expected term of its share-based awards. The simplified method computes the expected term as the sum of the award’s vesting term plus the original contractual term divided by two. Based on the lack of historical data of volatility for the Company’s common stock, the Company based its estimate of expected volatility on a weighted-average of the historical volatility of comparable public companies that manufacture similar products and are similar in size, stage of life cycle, and financial leverage. Restrictive stock awards On February 17, 2020, the Company granted a restricted stock award of 5,928,571 shares of the Company’s common stock to the Company’s Chief Executive Officer and then Interim Chief Financial Officer, Adam Levy, with the following vesting terms: (i) 3/12 th th On March 8, 2021, the Company granted a restricted stock award of 1,383,333 shares of the Company’s common stock to the Adam Levy for his service as our Chief Executive Officer and Chief Financial Officer from October 1, 2020 through September 30, 2021, all of which shares vested immediately. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ Number of ​ Grant Date ​ Units Fair Value Granted 7,311,904 ​ $ 0.023 Exercised and converted to common shares ​ (5,928,571) ​ ​ 0.014 Forfeited ​ — ​ ​ — Outstanding at December 31, 2020 ​ 1,383,333 ​ $ 0.060 Granted ​ — ​ ​ — Exercised and converted to common shares (1,383,333) ​ 0.060 Forfeited — ​ — Outstanding at June 30, 2021 — ​ $ — Exercisable at June 30,2021 — ​ $ — ​ Under ASC 718, Compensation-Stock Compensation (“ASC 718”), the Company has measured the value of its February 2020 award as if it were vested and issued on the grant date with a value of $83 thousand based on the closing price of the Company's stock at the grant date of the RSU Grant ($0.014 per share). An additional issuance of 1,383,333 shares was granted based on a closing price of the closing price of the Company’s stock at the grant date of the RSU Grant ($0.06 per share). As of June 30, 2021, there was approximately $21 thousand of total unrecognized share-based compensation related to restricted stock awards, which the Company expects to recognize over the next 6 months. Compensation expense will be recognized ratably over the total vesting schedule. The Company will periodically adjust the cumulative compensation expense for forfeited awards. Stock based compensation of $143 thousand and $104 thousand has been recorded for the six months ended June 30, 2021 and 2020, respectively. Warrants ​ The following table shows a summary of common stock warrants through June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average ​ ​ Number of ​ Exercise ​ Contractual ​ Warrants Price Term in Years Outstanding at December 31, 2019 5,250,000 ​ $ 0.014000 2.81 ​ ​ ​ ​ ​ ​ ​ ​ Granted 2,117,500 ​ $ 0.050720 5.00 Exercised — ​ — — Forfeited — ​ — — Cancelled — ​ — — Expired — ​ — — Outstanding at December 31, 2020 7,367,500 ​ $ 0.050720 2.54 Granted 12,460,000 ​ $ 0.135188 4.77 Exercised — ​ — — Forfeited — ​ — — Cancelled — ​ — — Expired — ​ — — Outstanding at June 30, 2021 19,827,500 ​ $ 0.094078 3.39 Exercisable at June 30, 2021 19,827,500 ​ $ 0.094078 3.39 ​ As of June 30, 2021, vested outstanding warrants had $561 thousand intrinsic value as the exercise price is greater than the estimated fair value of the underlying common stock.

Note Payable

Note Payable	6 Months Ended
	Jun. 30, 2021
Note Payable
Note Payable	13. Note Payable PPP Loan On April 22, 2020, the Company, entered into a promissory note (the “Promissory Note”) with PNC Bank, N.A. (the “Bank”), which provides for a loan in the amount of $147,300 (the “PPP Loan”) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). On March 4, 2021, the Company received a second PPP Loan in the amount of $127,400 thousand under Phase II of the Paycheck Protection Program which commenced on January 13, 2021 and allowed certain businesses that received an initial PPP Loan to seek a second draw PPP Loan. The PPP Loan has a two-year term and bears interest at a rate of 1.0% per annum. Monthly principal and interest payments are deferred for six months after the date of disbursement. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. The Promissory Note contains events of default and other provisions customary for a loan of this type. The Paycheck Protection Program provides that the PPP Loan may be partially or wholly forgiven if the funds are used for certain qualifying expenses as described in the CARES Act. The Company used the proceeds from the PPP Loan for qualifying expenses and plans to apply for forgiveness of the PPP Loan in accordance with the terms of the CARES Act. However, the Company cannot completely assure at this time that such forgiveness of the PPP Loan will occur. On June 2, 2021, the Company received notice from PNC Bank that its initial loan of $147,300 had been forgiven in its entirety by the SBA. The balance of the PPP loan as of June 30, 2021 and December 31, 2020 amounts to $127,400 and $147,300, respectively. Economic Injury Disaster Loan On May 28, 2020, the Company entered into the standard loan documents required for securing a loan (the “EIDL Loan”) from the SBA under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business. Pursuant to that certain Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan is up to $260,500, with proceeds to be used for working capital purposes. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due monthly beginning May 28, 2021 (twelve months from the date of the SBA Note in the amount of $1,270. The balance of principal and interest is payable thirty years from the date of the SBA Note. In connection therewith, the Company received an $8,000 advance, which does not have to be repaid. The balance of the EIDL Loan as of June 30, 2021 and December 31, 2020 amounts to $271,163 and $266,279, respectively.

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Jun. 30, 2021
Convertible Notes Payable
Convertible Notes Payable	14. Convertible Notes Payable On December 24, 2020, the Company entered into two Securities Purchase Agreement, dated December 24, 2020 (the “Purchase Agreement”) pursuant to which the Company issued the following (i) $100,000 6% Secured Convertible Promissory Note which was convertible into shares of the Company’s common stock at a price per share of $0.08 and (ii) Common Stock purchase warrants to purchase up to 312,500 shares of common stock with an exercise price of $0.08. The notes are secured by all of the assets and equipment owned by the Company. The notes were due on or before June 24, 2021 and fully-repaid (including all accrued but unpaid interest) on March 14, 2021. On January 19, 2021, the Company entered into a Securities Purchase Agreement, (the “2021 Purchase Agreement”) pursuant to which the Company issued the following (i) $15,000 Secured Convertible Promissory Note which was convertible into shares of the Company’s common stock at a price per share of $0.03. The notes were due on or before March 19, 2021 and fully-repaid (including all accrued but unpaid interest) on March 14, 2021. Auctus Fund Financing On March 11, 2021 (the “Issuance Date”), the Company entered into a securities purchase agreement (the “Auctus Purchase Agreement”) with Auctus Fund, LLC, a Delaware limited liability company (“Auctus”), pursuant to which the Company issued to Auctus a senior secured convertible promissory note in the principal amount of $1,500,000 (the “Auctus Note”). The net proceeds received by the Company were $1,337,000 (after deducting fees and expenses related to the transaction, including a payment to Alere (as defined and discussed below). The Company intends to use the net proceeds for working capital and general corporate purposes. On August 13, 2021, the Company and Auctus entered a First Amendment to the Senior Secured Promissory Note, Warrants and Securities Purchase Agreement dated March 11, 2011 (the “Auctus Amendment”). The Auctus Amendment is attached to this Form 10-Q as Exhibit 10.1 and is incorporated herein by reference. The Auctus Note has a maturity date of one year from the Issuance Date. The Auctus Note bears interest at a rate of 12% per annum, which is also payable on maturity, with the understanding that the first 12 months of interest (equal to $180,000) is guaranteed and deemed to be earned in full as of the Issuance Date. In the event the Company fails to pay any amount when due under the Auctus Note, the interest rate will increase to the greater of 16% or the maximum amount permitted by law. The Auctus Note may be prepaid during the first 180 calendar days from the Issuance Date subject to a 110% prepayment penalty on all principal and accrued but unpaid interest then outstanding. The Auctus Note may not be paid in whole or in part after 180 calendar days from the Issuance Date. Auctus may convert any amount due under the Auctus Note at any time, and from time to time, into shares of the Company’s common stock at a conversion price of $0.10 per share; provided, however, that Auctus may not convert any portion of the Auctus Note that would cause it to beneficially own in excess of 4.99% of the Company’s common stock. The conversion price and number of shares of the Company’s common stock issuable upon conversion of the Auctus Note will be subject to adjustment from time to time for any subdivision or consolidation of shares and other standard dilutive events. The Auctus Note (as amended by the Auctus Amendment) contains a number of events of default, including but not limited to the following: (i) the Company’s failure to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New York Stock Exchange, or the NYSE American by October 31, 2021 (the “Trading Date”) and (ii) the Company’s failure to file a registration statement covering the Auctus’ resale at prevailing market prices (and not fixed prices) of all of the common stock underlying the Auctus Note and the Auctus Warrants (as defined below) within 30 calendar days following the Issuance Date, (ii) cause the registration statement to become effective by the Trading Date. An event of default is subject to a confession of judgement against the Company in the favor of Auctus. Additionally, the Auctus Note is secured by all of the assets of the Company pursuant to a security agreement that was entered into in connection with the issuance of the Auctus Note (the “Security Agreement”); provided, however, the Security Agreement will be automatically terminated as of the Trading Date assuming no event of default then exists. The Auctus Amendment waived any events of default which may have existed under Sections 3.18 and 3.19 of the Auctus Note prior to August 13, 2021. In connection with the issuance of the Auctus Note, Auctus was also issued two five-year warrants as follows: the first warrant was to purchase up to an aggregate of 6,000,000 shares of the Company’s common stock at an exercise price of $0.125 per share (the “First Auctus Warrant”) and the second warrant was to purchase up to an aggregate of 5,000,000 shares of the Company’s common stock at an exercise price of $0.15 per share (the “Second Auctus Warrant”). The First Auctus Warrant and the Second Auctus Warrant are referred to herein as the “Auctus Warrants” and the shares of the Company’s common stock underlying the Auctus Warrants are referred to as the “Auctus Warrant Shares”. Auctus may not exercise the Auctus Warrants with respect to any number of Auctus Warrant Shares that would cause it to beneficially own in excess of 4.99% of the Company’s common stock. The Auctus Warrants may be exercised for cash, or, if the “market price” of the Company’s common stock is greater than the Auctus Warrant’s exercise price, and there is not an effective registration statement covering the Auctus Warrant Shares, the Auctus Warrants may be exercised on a cashless basis. The number of shares of common stock to be deliverable upon exercise of the Auctus Warrants is subject to adjustment for subdivision or consolidation of shares and other standard dilutive events, or in the event the Company effects a reorganization, reclassification, merger, consolidation, disposition of assets, or other fundamental transaction. Pursuant to the Auctus Purchase Agreement, the Company granted Auctus piggyback registration rights with respect to the shares underlying the Auctus Note and the Auctus Warrant. In addition, the Company agreed that, while any amount remains unpaid under the Auctus Note, it would not sell securities on more favorable terms than those provided to Auctus, without adjusting Auctus’ terms accordingly. Further, among other things, the Company agreed that, while any amount remains unpaid under the Auctus Note, it would not enter into any variable rate transactions. Further and in connection with the issuance of the Auctus Note, the Company entered into a registration rights agreement with Auctus (the “Registration Rights Agreement”) whereby it the Company agreed to (i) file with the Securities and Exchange Commission a registration statement covering resale by Auctus at prevailing market prices (and not fixed prices) of all of the common stock underlying the Auctus Note and the Auctus Warrants within 30 calendar days following the Issuance Date, (ii) cause the registration statement to become effective by the Trading Date. Alere Financial, A Division of Cova Capital Partners, LLC (“Alere”), served as the placement agent for the Auctus Note and received a total cash fee equal to $120,000 (or 8% of the principal amount of the Auctus Note). Additionally, Alere received warrants to purchase 654,545 and 545,455 shares of common stock at an exercise price equal to $0.125 and $0.15, respectively, for such services rendered. Alere’s warrants are in a customary form reasonably acceptable to Alere and exercisable for 3 years. Mr. Levy, the Company’s Chief Executive Officer and Chief Financial Officer, is affiliated with Alere but has waived any portion of such fee received by Alere to which he is entitled as an affiliate of Alere. As of June 30, 2021, the note outstanding was $510,904, which consisted of unamortized balance of $852,288 of a beneficial conversion and warrant features, unamortized original issue discount of $125,260 and unamortized debt issuance costs of $191,547.

Warrant Liability

Warrant Liability	6 Months Ended
	Jun. 30, 2021
Warrant Liability
Warrant Liability	15. Warrant Liability ​ On March 11, 2021, February 3, 2021, December 24, 2020, March 18, 2020, September 10, 2019 and November 6, 2019, the Company issued 1,200,000, 260,000, 255,000, 1,550,000, 1,250,000 and 4,000,000 warrants, respectively, as equity issuance consideration, in connection with a private placement of the Company’s common stock. The warrants entitle the holder to purchase one share of our common stock at an exercise price equal to $0.014 to $0.15 per share at any time on or after their issuance date and on or prior to the close of business 3 years after the issuance date (the “Termination Date”). The Company determined that these warrants are free standing financial instruments that are legally detachable and separately exercisable from the common stock included in the public share offering. Management also determined that the warrants required classification as a liability pursuant to ASC 815. In accordance with the accounting guidance, the outstanding warrants are recognized as a warrant liability on the balance sheet and are measured at their inception date fair value and subsequently re-measured at each reporting period with changes being recorded as a component of other income in the statement of operations. ​ The fair value of the warrant liabilities was measured using a Black-Scholes model. Significant inputs into the model at the inception are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Future ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated ​ ​ ​ ​ ​ Warrant ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Time to ​ Calculated ​ Quarterly ​ ​ Exercise ​ Expiration ​ ​ ​ Interest Rate ​ Volatility ​ Maturity ​ fair value ​ Dividend Black -Scholes Assumptions Price (1)(2) Date (1)(2) Stock Price (3) (annual) (4) ​ (annual) (5) ​ (Years) per share per share (6) March 11, 2021 ​ $ 0.125 – 0.15 ​ ​ March 11, 2024 ​ $ 0.10 ​ ​ 0.17 % ​ 172.54 % ​ 5.0 ​ $ 0.0093 - 0.0094 ​ $ — February 3, 2021 ​ $ 0.08 ​ ​ February 3, 2024 ​ $ 0.08 ​ ​ 0.18 % ​ 171.71 % ​ 3.0 ​ $ 0.0690703 ​ $ — December 24, 2020 ​ $ 0.08 ​ ​ December 24, 2020 ​ $ 0.08 ​ ​ 0.17 % ​ 172.54 % ​ 3.0 ​ $ 0.0692188 ​ $ — March 18, 2020 ​ $ 0.04 ​ ​ March 18, 2020 ​ $ 0.04 ​ ​ 0.66 % ​ 137.41 % ​ 3.0 ​ $ 0.0307299 ​ $ — September 10, 2019 ​ $ 0.014 ​ ​ September 10, 2022 ​ $ 0.014 ​ ​ 1.61 % ​ 139.84 % ​ 3.0 ​ $ 0.01091 ​ $ — November 6, 2019 ​ $ 0.014 ​ ​ November 6, 2022 ​ $ 0.014 ​ ​ 1.60 % ​ 138.48 % ​ 3.0 ​ $ 0.01095 ​ $ — ​ Significant inputs into the model at the reporting period measurement dates are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Future ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated ​ ​ ​ ​ ​ Warrant ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Time to ​ Calculated ​ Quarterly ​ ​ Exercise ​ Expiration ​ ​ ​ ​ Interest Rate ​ Volatility ​ Maturity ​ fair value ​ Dividend Black-Scholes Assumptions Price (1)(2) Date (1)(2) ​ Stock Price (3) ​ (annual) (4) ​ (annual) (5) (Years) per share per share (6) June 30, 2021 ​ $ ​ ​ March 11, 2024 ​ $ 0.10 ​ ​ 0.87 % ​ 170.53 % ​ 4.70 ​ $ 0.0093 - 0.0094 ​ $ — June 30, 2021 ​ $ 0.08 ​ ​ February 3, 2024 ​ $ 0.08 ​ ​ 0.87 % ​ 170.53 % ​ 4.70 ​ $ 0.0692188 ​ $ — June 30, 2021 ​ $ 0.08 ​ ​ December 24, 2020 ​ $ 0.08 ​ ​ 0.25 % ​ 170.53 % ​ 2.60 ​ $ 0.0692188 ​ $ — June 30, 2021 ​ $ 0.04 ​ March 18, 2020 ​ $ 0.04 ​ ​ 0.25 % ​ 170.53 % 2.48 ​ $ 0.0307299 ​ $ — June 30, 2021 ​ $ 0.014 ​ September 10, 2022 ​ $ 0.014 ​ ​ 0.07 % ​ 170.53 % 1.72 ​ $ 0.01091 ​ $ — June 30, 2021 ​ $ 0.014 ​ November 6, 2022 ​ $ 0.014 ​ ​ 0.07 % ​ 170.53 % 1.20 ​ $ 0.01095 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Future ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated ​ ​ ​ ​ ​ Warrant ​ ​ ​ ​ Interest ​ ​ ​ ​ Time to ​ Calculated ​ Quarterly ​ ​ Exercise ​ Expiration ​ Stock ​ Rate ​ Volatility ​ Maturity ​ fair value ​ Dividend Black-Scholes Assumptions ​ Price (1)(2) ​ Date (1)(2) ​ Price (3) ​ (annual) (4) ​ (annual) (5) ​ (Years) ​ per share ​ per share (6) December 31, 2020 ​ $ 0.08 ​ ​ December 24, 2020 ​ $ 0.08 ​ ​ 0.17 % ​ 172.38 % ​ 2.98 ​ $ 0.0692188 ​ $ — December 31, 2020 ​ $ 0.04 ​ ​ March 18, 2023 ​ $ 0.04 ​ ​ 0.13 % ​ 172.38 % ​ 2.21 ​ $ 0.0307299 ​ $ — December 31, 2020 ​ $ 0.014 ​ ​ September 10, 2022 ​ $ 0.014 ​ ​ 0.13 % ​ 172.38 % ​ 1.85 ​ $ 0.01091 ​ $ — December 31, 2020 ​ $ 0.014 ​ November 6, 2022 ​ $ 0.014 ​ ​ 1.13 % ​ 172.38 % ​ 1.69 ​ $ 0.01095 ​ $ — (1) Based on the terms provided in the warrant agreement related to the issuance of common stock of on March 11 th , 2021 (2) Based on the terms provided in the warrant agreement related to the issuance of common stock of on February 3 rd , 2021 (3) Based on the terms provided in the warrant agreement related to the issuance of common stock of on December 24 th , 2020 (4) Based on the terms provided in the warrant agreement related to the issuance of common stock of on March 18 th , 2020 (5) Based on the terms provided in the warrant agreement related to the issuance of common stock of on September 10 th , 2019 (6) Based on the terms provided in the warrant agreement related to the issuance of common stock of on November 6 th , 2019 (7) Based on the observable transaction value of common stock of per the most recent stock issuance financing agreements. (8) Interest rate for U.S. Treasury Bonds, as of the issuance dates and each presented period ending date, as published by the U.S. Federal Reserve. (9) Based on the historical daily volatility of Guideline Public Companies and each presented period ending date. (10) Current estimated dividend payments beyond initial four quarters. At a future date, the company will review the working capital needs and make a final determination of any future dividend payments. The warrants outstanding and fair values at each of the respective valuation dates are summarized below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants Fair Value ​ ​ Warrant Liability ​ Outstanding ​ per Share ​ Fair Value Fair Value as of period ending 12/31/19 5,250,000 ​ $ 0.01086 ​ $ 56 ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value at initial measurement date ​ 1,805,000 ​ $ 0.03616 ​ $ 65 Change in fair value of warrant liability ​ ​ ​ ​ ​ ​ 2 Fair Value as of period ending 12/31/20 ​ 7,055,000 ​ ​ ​ ​ $ 123 Fair Value at initial measurement dates 1,460,000 ​ $ 0.08273 ​ $ 130 Change in fair value of warrant liability ​ ​ ​ ​ (8) Fair Value as of period ending 6/30/2021 8,515,000 ​ ​ ​ ​ $ 245 ​

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions
Related Party Transactions	16. Related Party Transactions Convertible Promissory Note On December 24, 2020, the Company issued two Secured Convertible Promissory Notes in an aggregate amount of $100,000 to Mr. Stein, a member of the board of directors and an entity affiliated to Mr. Stein, N&F Trust 774 (See Note 14). The notes were repaid in March 2021. Advances Dr. Jerome Zeldis, a member of the Company Board, has an outstanding balance due of $30,000 for services as of December 31, 2020. The fees were paid in February 2021. Sports Defense Acquisition On May 29, 2020, the Company entered into a Membership Interest Purchase Agreement whereby the Company purchased all of the outstanding equity securities of Sport Defense LLC. , Adam Levy, the Company’s Chief Executive Officer and Chief Financial Officer, and Nachum Stein, a member of the Company’s Board of Directors (the “Board”), were each members of Sport Defense and part of the Sellers. Mr. Levy received 1,546,875 of the shares and Mr. Stein received 3,187,500 of the shares (See Note 3).

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events
Subsequent Events	17. Subsequent Events The Company has evaluated subsequent events for the potential recognition or disclosure through August 16, 2021, the date the financial statements were available to be issued, and has determined that the following matter should be disclosed in the accompanying condensed financial statements. On August 2, 2021, the Company filed an amendment to its certificate of incorporation to decrease the number of the Company’s authorized shares of common stock from 3,000,000,000 shares of common stock to 750,000,000 shares of common stock. On August 13, 2021, the Company and Auctus Fund, LLC entered a First Amendment to the Senior Secured Promissory Note, Warrants and Securities Purchase Agreement dated March 11, 2011 (the “Auctus Amendment”). The Auctus Amendment is attached to this Form 10-Q as Exhibit 10.1, is incorporated herein by reference and is more fully described in Footnote 14 above.

Description of Business, the _2

Description of Business, the Spin-off and Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2021
Description of Business, the Spin-off and Basis of Presentation
Accounts receivable, net	Accounts receivable, net Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable and records a provision to the allowance for doubtful accounts based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded in selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for doubtful accounts was $4 thousand as of June 30, 2021 and $1 thousand as of December 31, 2020.
Inventory	Inventory Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. The Company evaluates inventories for excess quantities, obsolescence or shelf-life expiration. This evaluation includes an analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf-life expiration dates for products. These factors determine when, and if, the Company adjusts the carrying value of inventory to estimated net realizable value. The balance is made up of raw materials of $189 thousand and $190 thousand, work-in-progress of $23 thousand and $22 thousand, and finished goods of $14 thousand and $21 thousand on June 30, 2021 and December 31, 2020, respectively.
Property and equipment, net	Property and equipment, net Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. Repairs and maintenance costs are expensed as incurred. Management periodically assesses the estimated useful life over which assets are depreciated or amortized. If the analysis warrants a change in the estimated useful life of property and equipment, management will reduce the estimated useful life and depreciate or amortize the carrying value prospectively over the shorter remaining useful life. The carrying amounts of assets sold or retired and the related accumulated depreciation are eliminated in the period of disposal and the resulting gains and losses are included in the results of operations during the same period.
Goodwill and Intangible Assets	Goodwill and Intangible Assets In applying the acquisition method of accounting, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Identifiable intangible assets are initially valued at fair value using generally accepted valuation methods appropriate for the type of intangible asset. Identifiable intangible assets with definite lives are amortized over their estimated useful lives and are reviewed for impairment if indicators of impairment arise. Intangible assets with indefinite lives are tested for impairment within one year of acquisitions or annually as of December 1, and whenever indicators of impairment exist. The fair value of intangible assets is compared with their carrying values, and an impairment loss would be recognized for the amount by which a carrying amount exceeds its fair value. Acquired identifiable intangible assets are amortized over the following periods: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Expected Life Acquired intangible Asset Amortization Basis (years) Technology-Related Straight-line basis 3 Marketing-Related Straight-line basis 4
Impairment of Long-lived assets	Impairment of Long-Lived Assets We review the recoverability of our long-lived assets, including equipment and right-of-use assets, when events or changes in circumstances occur that indicate that the carrying value of the asset, or asset group, may not be recoverable. Events or circumstances that might cause management to perform impairment testing include, but are not limited to, significant underperformance relative to historical or projected future operating results of the asset or asset group, significant changes in the manner or use of assets or the strategy for our overall business; and significant negative industry or economic trends. If indicators of potential impairment are present, management performs a recoverability test and, if necessary, records an impairment loss. If the total estimated future undiscounted cash flows to be generated from the use and ultimate disposition of an asset or asset group is less than its carrying value, an impairment loss is recorded in the Company’s results of operations, measured as the amount required to reduce the carrying value to fair value. Fair value is determined in accordance with the best available information per the hierarchy described under Fair Value Measurements
Prepaid expenses and other current assets	Prepaid expenses and other current assets Prepaid expenses and other current assets is recorded at historical cost and is primarily made up of $26 thousand and $16 thousand of prepaid insurance, and $56 thousand and $9 thousand general prepaid expenses and other current assets in the period ended June 30, 2021 and December 31, 2020, respectively.
Other Assets	Other Assets Other Assets is recorded at historical costs, and as of June 30, 2021 and December 31, 2020, the balance is entirely made up of spare parts for manufacturing equipment. Other assets are stated at cost and are not subject to depreciation, until such time that they are placed into service and the part that is being replaced is disposed.
Fair value measurements	Fair value measurements The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: Level 1 Level 2 Level 3 The Company considers the carrying amounts of its financial instruments (cash, accounts receivable and accounts payable) in the balance sheet to approximate fair value because of the short-term or highly liquid nature of these financial instruments.
Warrant Liability	Warrant Liability Warrants to purchase common stock were issued in connection with equity financing raises, which occurred on March 11, 2021, February 3, 2021, December 24, 2020, March 18, 2020, September 10, 2019 and November 6, 2019. The fair values of the warrants are estimated as of the date of issuance and again at each period end using a Black-Scholes option valuation model. At issuance, the fair value of the warrant is recognized as an equity issuance cost within additional paid-in-capital. Fair value adjustments to the warrant liability are recognized in other income (expense) in the statements of operations.
Revenue recognition	Revenue recognition On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers The Company recognizes revenue predominately from three types of revenue, contract manufacturing, custom and white label manufacturing and proprietary branded products. Revenue from contract manufacturing is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. The Company’s customers consist of other life sciences companies and revenues are concentrated in the United States. Payment terms vary by the type and location of customer and may differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 60 days from date of shipment. Estimates for product returns, allowances and discounts are recorded as a reduction of revenue and are established at the time of sale. Returns are estimated through a comparison of historical return data and are determined for each product and adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have not been material. Amounts accrued for sales allowances and discounts are based on estimates of amounts that are expected to be claimed on the related sales and are based on historical data. Payments for allowances and discounts have historically been immaterial. Disaggregated revenue by sales type: ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ June 30, ​ 2021 2020 Contract manufacturing ​ $ 379 ​ $ 331 Custom and white label finished goods manufacturing ​ 194 ​ — Nexgel branded consumer products ​ 110 ​ — ​ ​ ​ ​ ​ ​ ​ Total ​ $ 683 ​ $ 331 ​ As of June 30, 2021, the Company did not have any contract assets or contract liabilities from contracts with customers. As of June 30, 2021, there were no remaining performance obligations that the Company had not satisfied.
Share-based compensation	Share-based compensation On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan (the “2019 Plan”). The 2019 Plan provides for the granting of incentive stock options, nonqualified stock options, restricted stock, stock appreciation rights (“SARs”), restricted stock units, performance awards, dividend equivalent rights and other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash, shares of common stock of the Company or a combination of cash and shares of common stock of the Company. The Company initial reserved a total of 2,000,000 shares of the Company’s common stock for awards under the 2019 Plan. Effective as of May 26, 2020 and May 3, 2021, respectively, the Board approved an increase of the number of authorized shares of common stock reserved under the 2019 Plan from 2,000,000 shares of common stock to 17,000,000 shares of common stock and from 17,000,000 shares of common stock to 20,000,000 shares of common stock, all of which may be delivered pursuant to incentive stock options. Subject to adjustments pursuant to the 2019 Plan, the maximum number of shares of common stock with respect to which stock options or SARs may The Company’s 2019 Long-Term Incentive Plan provides certain employees, contractors and outside directors with share-based compensation in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. Forfeitures are accounted for when they occur. In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-07, Compensation - Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting Compensation - Stock Compensation
Income taxes	Income taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed.
Segment reporting	Segment reporting The Company operates in one business segment as a contract manufacturer of aqueous polymer hydrogels. As a result, the Company’s operations are a single reportable segment, which is consistent with the Company’s internal management reporting.
Comprehensive loss	Comprehensive loss Comprehensive loss consists of net loss and changes in equity during a period from transactions and other equity and circumstances generated from non-owner sources. The Company’s net loss equals comprehensive loss for all periods presented,
Recently Adopted and Issued Accounting Standards	Recently Adopted Accounting Standards In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) Recently Issued Accounting Standards From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. Fair Value Measurement—Disclosure Framework In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement

Description of Business, the _3

Description of Business, the Spin-off and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2021
Description of Business, the Spin-off and Basis of Presentation
Schedule of net liabilities assumed pursuant to Spin-Off and in exchange	Pursuant to the Spin-Off and in exchange for the 5,005,211 shares of common stock,NexGel assumed the following net assets and liabilities from Parent as of June 21, 2019 ($ in thousands): ​ ​ ​ ​ ​ Assets: ​ ​ Cash ​ $ 186 Accounts receivable, net ​ 72 Inventory, net ​ 140 Prepaid expenses and other current assets ​ 101 Property and equipment, net ​ 155 Operating lease - right of use asset ​ 976 Other assets ​ 178 Total assets ​ 1,808 ​ ​ ​ ​ Liabilities: ​ ​ ​ Accounts payable ​ (496) Accrued expenses and other current liabilities ​ (395) Operating lease liability - current ​ (207) Long-term operating lease liability ​ (769) Total liabilities ​ (1,867) ​ ​ ​ ​ Net liabilities assumed in Spin-Off on June 21, 2019 ​ $ (59)
Acquired identifiable intangible assets amortized period	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Expected Life Acquired intangible Asset Amortization Basis (years) Technology-Related Straight-line basis 3 Marketing-Related Straight-line basis 4
Disaggregated revenue by sales	​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ June 30, ​ 2021 2020 Contract manufacturing ​ $ 379 ​ $ 331 Custom and white label finished goods manufacturing ​ 194 ​ — Nexgel branded consumer products ​ 110 ​ — ​ ​ ​ ​ ​ ​ ​ Total ​ $ 683 ​ $ 331

Acquisition (Tables)

Acquisition (Tables)	6 Months Ended
	Jun. 30, 2021
Acquisition
Schedule of preliminary analysis for the Sports Defense acquisition	​ ​ ​ ​ ​ Provisional Purchase Consideration at preliminary fair value: ​ Purchase price ​ $ 375 Amount of consideration ​ $ 375 ​ ​ ​ ​ Assets acquired and liabilities assumed at preliminary fair value ​ Inventories ​ 21 Product/Technology related intangibles ​ ​ 31 Marketing related intangibles ​ ​ 8 Customer related intangibles ​ ​ 17 Accounts payable and accrued expenses ​ (13) Other liabilities ​ — Net tangible assets acquired ​ $ 64 ​ ​ ​ ​ Total net assets acquired ​ $ 64 Consideration paid ​ 375 Preliminary goodwill ​ $ 311
Schedule of unaudited pro-forma results of operations	​ ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months Ended ​ ​ June 30, ​ 2021 2020 Revenues, net ​ $ 683 ​ $ 348 Net loss allocable to common shareholders ​ $ (1,529) ​ $ (1,029) Net loss per share ​ $ (0.01) ​ $ (0.01) Weighted average number of shares outstanding ​ 102,156,565 ​ 78,258,316

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases
Schedule of future minimum lease payments, excluding expense reimbursements, under noncancelable operating leases	The following table presents information about the amount and timing of the liability arising from the Company’s operating lease as of June 30, 2021 ($ in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Operating ​ ​ ​ Lease ​ Maturity of Lease Liability ​ Liability ​ 2021 (remainder of year) $ 104 ​ 2022 ​ 207 ​ 2023 ​ 207 ​ 2024 ​ ​ 207 ​ 2025 ​ 207 ​ Thereafter ​ ​ 1,428 ​ Total undiscounted operating lease payments ​ $ 2,360 ​ Less: Imputed interest ​ (335) ​ Present value of operating lease liability ​ $ 2,025 ​ Weighted average remaining lease term ​ ​ 9.6 years ​ Weighted average discount rate ​ ​ 3.0 % ​
Schedule of Summary of supplemental cash flows information related to leases	Supplemental cash flows information related to leases was as follows ($ in thousands): ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2021 ​ Cash paid for amounts included in the measurement of lease liability: ​ ​ ​ ​ Operating cash flows from operating lease ​ $ 109 ​ Change in right-of-use asset/liability due to lease amendments ​ $ 1,275 ​

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory
Schedule of inventories	Inventory consists of the following ($ in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 Raw materials ​ $ 189 ​ $ 190 Work-in-progress ​ ​ 23 ​ ​ 22 Finished goods ​ ​ 14 ​ ​ 21 ​ ​ ​ 226 ​ ​ 233 Less: Inventory reserve for excess and slow moving inventory ​ — ​ — Total ​ $ 226 ​ $ 233

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2021
Property and Equipment, Net
Schedule of property and equipment, net	Property and equipment consist of the following ($ in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Useful Life June 30, December 31, ​ ​ (Years) ​ 2021 ​ 2020 Machinery and equipment ​ 3 - 10 ​ $ 940 ​ $ 2,894 Office furniture and equipment 3 - 10 ​ 49 ​ 49 Leasehold improvements 6 ​ 228 ​ 228 Construction in progress ​ N/A ​ ​ — ​ ​ 461 ​ ​ ​ 1,217 ​ 3,632 Less: accumulated depreciation and amortization ​ ​ (446) ​ (3,079) Property and equipment, net $ 771 $ 553

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Intangible Assets
Schedule of identifiable intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 Product/Technology Related ​ ​ ​ ​ Identifiable intangible assets, gross ​ $ 31 ​ $ 31 Accumulated amortization ​ (11) ​ ​ (6) Product/Technology Related identifiable intangible assets, net ​ 20 ​ ​ 25 Marketing Related ​ ​ ​ ​ Customer related intangible asset, gross ​ ​ 17 ​ ​ 17 Tradename related intangible asset, gross ​ 7 ​ ​ 7 Accumulated amortization ​ (4) ​ ​ (2) Marketing related identifiable intangible assets, net ​ 20 ​ ​ 22 Total Identifiable intangible assets, net ​ $ 40 ​ $ 47
Schedule of estimated annual amortization expense	As of June 30, 2021, the estimated annual amortization expense for each of the next five fiscal years is as follows: ​ ​ ​ ​ ​ 2021 (remainder of year) $ 7 2022 ​ 14 2023 ​ 8 2024 ​ 3 2025 ​ 2 Thereafter ​ ​ 6 Total ​ $ 40

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Accrued Expenses and Other Current Liabilities
Schedule of accrued expenses and other current liabilities	Accrued expenses and other current liabilities consist of the following ($ in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2021 ​ 2020 Salaries, benefits and incentive compensation ​ $ 47 ​ $ 43 Other ​ 23 ​ 47 Total accrued expenses and other current liabilities ​ $ 70 ​ $ 90

Common Stock (Tables)

Common Stock (Tables)	6 Months Ended
	Jun. 30, 2021
Common Stock
Summary of reserved of common stock for issuance	As of June 30, 2021, the Company has reserved common stock for issuance in relation to the following: ​ ​ ​ ​ Share-based compensation plan 17,000,000 Warrants to purchase common stock 19,827,500

Share-based Compensation (Table

Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Compensation
Schedule of information about 2019 plan	The following table contains information about the 2019 Plan as of June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ Awards ​ Awards ​ ​ Reserved for ​ ​ ​ Available for ​ ​ Issuance ​ Awards Issued ​ Grant 2019 Plan 17,000,000 14,705,949 2,294,051
Schedule of incentive stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average ​ ​ Number of ​ Exercise ​ Contractual ​ ​ Options ​ Price ​ Term in Years Outstanding at January 1, 2020 1,000,000 $ 0.053525 9.6 Granted 12,705,949 ​ $ 0.0291 10.0 Exercised — ​ — — Forfeited — ​ — — Cancelled — ​ — — Expired — ​ — — Outstanding at December 31, 2020 ​ 13,705,949 ​ $ 0.027736 ​ 9.32 ​ ​ ​ ​ ​ ​ ​ ​ Granted ​ 1,666,667 ​ $ 0.08 ​ 10.0 Exercised ​ — ​ ​ — ​ — Forfeited ​ — ​ ​ — ​ — Cancelled ​ — ​ ​ — ​ — Expired ​ — ​ ​ — ​ — Outstanding at June 30, 2021 15,372,616 ​ $ 0.034889 8.91 Exercisable at June 30, 2021 ​ 9,105,949 ​ $ 0.025441 ​ 8.75
Schedule of assumptions used in share-based compensation	The following assumptions were used to calculate share-based compensation expense for six months ended June 30, 2021: ​ ​ ​ ​ ​ Volatility 171.12%- 172.19 % Risk-free interest rate ​ 0.46% - 0.86 % Dividend yield 0.0 % Expected term 5.0 – 5.25 years
Schedule of restricted stock awards activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ Number of ​ Grant Date ​ Units Fair Value Granted 7,311,904 ​ $ 0.023 Exercised and converted to common shares ​ (5,928,571) ​ ​ 0.014 Forfeited ​ — ​ ​ — Outstanding at December 31, 2020 ​ 1,383,333 ​ $ 0.060 Granted ​ — ​ ​ — Exercised and converted to common shares (1,383,333) ​ 0.060 Forfeited — ​ — Outstanding at June 30, 2021 — ​ $ — Exercisable at June 30,2021 — ​ $ —
Summary of common stock warrants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average ​ ​ Number of ​ Exercise ​ Contractual ​ Warrants Price Term in Years Outstanding at December 31, 2019 5,250,000 ​ $ 0.014000 2.81 ​ ​ ​ ​ ​ ​ ​ ​ Granted 2,117,500 ​ $ 0.050720 5.00 Exercised — ​ — — Forfeited — ​ — — Cancelled — ​ — — Expired — ​ — — Outstanding at December 31, 2020 7,367,500 ​ $ 0.050720 2.54 Granted 12,460,000 ​ $ 0.135188 4.77 Exercised — ​ — — Forfeited — ​ — — Cancelled — ​ — — Expired — ​ — — Outstanding at June 30, 2021 19,827,500 ​ $ 0.094078 3.39 Exercisable at June 30, 2021 19,827,500 ​ $ 0.094078 3.39

Warrant Liability (Tables)

Warrant Liability (Tables)	6 Months Ended
	Jun. 30, 2021
Warrant Liability
Schedule of warrant liability	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Future ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated ​ ​ ​ ​ ​ Warrant ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Time to ​ Calculated ​ Quarterly ​ ​ Exercise ​ Expiration ​ ​ ​ Interest Rate ​ Volatility ​ Maturity ​ fair value ​ Dividend Black -Scholes Assumptions Price (1)(2) Date (1)(2) Stock Price (3) (annual) (4) ​ (annual) (5) ​ (Years) per share per share (6) March 11, 2021 ​ $ 0.125 – 0.15 ​ ​ March 11, 2024 ​ $ 0.10 ​ ​ 0.17 % ​ 172.54 % ​ 5.0 ​ $ 0.0093 - 0.0094 ​ $ — February 3, 2021 ​ $ 0.08 ​ ​ February 3, 2024 ​ $ 0.08 ​ ​ 0.18 % ​ 171.71 % ​ 3.0 ​ $ 0.0690703 ​ $ — December 24, 2020 ​ $ 0.08 ​ ​ December 24, 2020 ​ $ 0.08 ​ ​ 0.17 % ​ 172.54 % ​ 3.0 ​ $ 0.0692188 ​ $ — March 18, 2020 ​ $ 0.04 ​ ​ March 18, 2020 ​ $ 0.04 ​ ​ 0.66 % ​ 137.41 % ​ 3.0 ​ $ 0.0307299 ​ $ — September 10, 2019 ​ $ 0.014 ​ ​ September 10, 2022 ​ $ 0.014 ​ ​ 1.61 % ​ 139.84 % ​ 3.0 ​ $ 0.01091 ​ $ — November 6, 2019 ​ $ 0.014 ​ ​ November 6, 2022 ​ $ 0.014 ​ ​ 1.60 % ​ 138.48 % ​ 3.0 ​ $ 0.01095 ​ $ — ​ Significant inputs into the model at the reporting period measurement dates are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Future ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated ​ ​ ​ ​ ​ Warrant ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Time to ​ Calculated ​ Quarterly ​ ​ Exercise ​ Expiration ​ ​ ​ ​ Interest Rate ​ Volatility ​ Maturity ​ fair value ​ Dividend Black-Scholes Assumptions Price (1)(2) Date (1)(2) ​ Stock Price (3) ​ (annual) (4) ​ (annual) (5) (Years) per share per share (6) June 30, 2021 ​ $ ​ ​ March 11, 2024 ​ $ 0.10 ​ ​ 0.87 % ​ 170.53 % ​ 4.70 ​ $ 0.0093 - 0.0094 ​ $ — June 30, 2021 ​ $ 0.08 ​ ​ February 3, 2024 ​ $ 0.08 ​ ​ 0.87 % ​ 170.53 % ​ 4.70 ​ $ 0.0692188 ​ $ — June 30, 2021 ​ $ 0.08 ​ ​ December 24, 2020 ​ $ 0.08 ​ ​ 0.25 % ​ 170.53 % ​ 2.60 ​ $ 0.0692188 ​ $ — June 30, 2021 ​ $ 0.04 ​ March 18, 2020 ​ $ 0.04 ​ ​ 0.25 % ​ 170.53 % 2.48 ​ $ 0.0307299 ​ $ — June 30, 2021 ​ $ 0.014 ​ September 10, 2022 ​ $ 0.014 ​ ​ 0.07 % ​ 170.53 % 1.72 ​ $ 0.01091 ​ $ — June 30, 2021 ​ $ 0.014 ​ November 6, 2022 ​ $ 0.014 ​ ​ 0.07 % ​ 170.53 % 1.20 ​ $ 0.01095 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Future ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated ​ ​ ​ ​ ​ Warrant ​ ​ ​ ​ Interest ​ ​ ​ ​ Time to ​ Calculated ​ Quarterly ​ ​ Exercise ​ Expiration ​ Stock ​ Rate ​ Volatility ​ Maturity ​ fair value ​ Dividend Black-Scholes Assumptions ​ Price (1)(2) ​ Date (1)(2) ​ Price (3) ​ (annual) (4) ​ (annual) (5) ​ (Years) ​ per share ​ per share (6) December 31, 2020 ​ $ 0.08 ​ ​ December 24, 2020 ​ $ 0.08 ​ ​ 0.17 % ​ 172.38 % ​ 2.98 ​ $ 0.0692188 ​ $ — December 31, 2020 ​ $ 0.04 ​ ​ March 18, 2023 ​ $ 0.04 ​ ​ 0.13 % ​ 172.38 % ​ 2.21 ​ $ 0.0307299 ​ $ — December 31, 2020 ​ $ 0.014 ​ ​ September 10, 2022 ​ $ 0.014 ​ ​ 0.13 % ​ 172.38 % ​ 1.85 ​ $ 0.01091 ​ $ — December 31, 2020 ​ $ 0.014 ​ November 6, 2022 ​ $ 0.014 ​ ​ 1.13 % ​ 172.38 % ​ 1.69 ​ $ 0.01095 ​ $ — (1) Based on the terms provided in the warrant agreement related to the issuance of common stock of on March 11 th , 2021 (2) Based on the terms provided in the warrant agreement related to the issuance of common stock of on February 3 rd , 2021 (3) Based on the terms provided in the warrant agreement related to the issuance of common stock of on December 24 th , 2020 (4) Based on the terms provided in the warrant agreement related to the issuance of common stock of on March 18 th , 2020 (5) Based on the terms provided in the warrant agreement related to the issuance of common stock of on September 10 th , 2019 (6) Based on the terms provided in the warrant agreement related to the issuance of common stock of on November 6 th , 2019 (7) Based on the observable transaction value of common stock of per the most recent stock issuance financing agreements. (8) Interest rate for U.S. Treasury Bonds, as of the issuance dates and each presented period ending date, as published by the U.S. Federal Reserve. (9) Based on the historical daily volatility of Guideline Public Companies and each presented period ending date. (10) Current estimated dividend payments beyond initial four quarters. At a future date, the company will review the working capital needs and make a final determination of any future dividend payments. The warrants outstanding and fair values at each of the respective valuation dates are summarized below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants Fair Value ​ ​ Warrant Liability ​ Outstanding ​ per Share ​ Fair Value Fair Value as of period ending 12/31/19 5,250,000 ​ $ 0.01086 ​ $ 56 ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value at initial measurement date ​ 1,805,000 ​ $ 0.03616 ​ $ 65 Change in fair value of warrant liability ​ ​ ​ ​ ​ ​ 2 Fair Value as of period ending 12/31/20 ​ 7,055,000 ​ ​ ​ ​ $ 123 Fair Value at initial measurement dates 1,460,000 ​ $ 0.08273 ​ $ 130 Change in fair value of warrant liability ​ ​ ​ ​ (8) Fair Value as of period ending 6/30/2021 8,515,000 ​ ​ ​ ​ $ 245

Description of Business, the _4

Description of Business, the Spin-off and Basis of Presentation (Details)	Apr. 22, 2019shares	Jan. 31, 2021segment	Aug. 02, 2021shares	Jun. 30, 2021USD ($)shares	May 03, 2021shares	May 02, 2021shares	Dec. 31, 2020USD ($)	May 26, 2020shares	May 25, 2020shares	Aug. 28, 2019shares	Jun. 21, 2019USD ($)
Description of Business, the Spin-off and Basis of Presentation
Number of operating segments | segment		1
Allowance for doubtful accounts				$ 4,000			$ 1,000
Raw materials				189,000			190,000
Work-in-progress				23,000			22,000
Finished goods				14,000			21,000
prepaid insurance				26,000			16,000
General prepaid expenses				56,000			9,000
Remaining performance obligations				0
Assets:
Cash				382,000			32,000
Accounts receivable, net				219,000			73,000
Inventory, net				226,000			233,000
Prepaid expenses and other current assets				82,000			25,000
Property and equipment, net				771,000			553,000
Operating lease - right of use asset				2,019,000			805,000
Other assets				60,000			178,000
Total assets				4,110,000			2,257,000
Liabilities:
Accounts payable				(592,000)			(657,000)
Accrued expenses and other current liabilities				(70,000)			(90,000)
Operating lease liability - current				(207,000)			(207,000)
Long-term operating lease liability				(1,818,000)			(598,000)
Total liabilities				$ (3,841,000)			$ (2,185,000)
Subsequent Events
Description of Business, the Spin-off and Basis of Presentation
Common stock reserved for issuance | shares			3,000,000,000
2019 Plan
Description of Business, the Spin-off and Basis of Presentation
Common stock reserved for issuance | shares				17,000,000	20,000,000	17,000,000		17,000,000	2,000,000	2,000,000
Number of shares available for grant | shares				14,705,949
2019 Plan | Subsequent Events
Description of Business, the Spin-off and Basis of Presentation
Common stock reserved for issuance | shares			750,000,000
2019 Plan | Executive officer
Description of Business, the Spin-off and Basis of Presentation
Number of shares available for grant | shares					500,000			500,000		500,000
The Spin-Off
Description of Business, the Spin-off and Basis of Presentation
Number of shares received by holder of each common stock | shares	1
Shares distributed | shares	5,005,211
Assets:
Cash											$ 186,000
Accounts receivable, net											72,000
Inventory, net											140,000
Prepaid expenses and other current assets											101,000
Property and equipment, net											155,000
Operating lease - right of use asset											976,000
Other assets											178,000
Total assets											1,808,000
Liabilities:
Accounts payable											(496,000)
Accrued expenses and other current liabilities											(395,000)
Operating lease liability - current											(207,000)
Long-term operating lease liability											(769,000)
Total liabilities											(1,867,000)
Net liabilities assumed in Spin-Off on June 21, 2019											$ (59,000)

Description of Business, the _5

Description of Business, the Spin-off and Basis of Presentation - Acquired intangible asset and amortization basis (Details)	6 Months Ended
	Jun. 30, 2021
Product/Technology Related
Acquired Finite-Lived Intangible Assets [Line Items]
Expected life	3 years
Marketing-Related
Acquired Finite-Lived Intangible Assets [Line Items]
Expected life	4 years

Description of Business, the _6

Description of Business, the Spin-off and Basis of Presentation - Disaggregated revenue by sales (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Description of Business, the Spin-off and Basis of Presentation
Contract manufacturing			$ 379	$ 331
Custom and white label finished goods manufacturing			194	0
Nexgel branded consumer products			110	0
Total	$ 417	$ 91	$ 683	$ 331

Going Concern (Details)

Going Concern (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Going Concern
Cash	$ 382,000				$ 382,000
Net loss	$ (826,000)	$ (704,000)	$ (530,000)	$ (508,000)	(1,529,000)	$ (1,038,000)
Net cash used in operating activities					(1,033,000)	$ (980,000)
Working capital deficit					$ 860,000

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - $ / shares	Apr. 22, 2019	Jun. 30, 2021	Dec. 31, 2020
Net Loss Per Common Share
Common stock, par value		$ 0.001	$ 0.001
The Spin-Off
Net Loss Per Common Share
Shares distributed	5,005,211

Acquisition (Details)

Acquisition (Details) - USD ($)	May 29, 2020	Jun. 30, 2021	Dec. 31, 2020
Provisional Purchase Consideration at preliminary fair value:
Common stock, par value		$ 0.001	$ 0.001
Sports Defense LLC
Provisional Purchase Consideration at preliminary fair value:
Purchase price	$ 375
Issuance of common stock for acquisition (in shares)	9,375,000
Common stock, par value	$ 0.001
Share purchase price	$ 0.04
Net assets acquired	$ 375,000
Mr. Levy | Sports Defense LLC
Provisional Purchase Consideration at preliminary fair value:
Issuance of common stock for acquisition (in shares)	1,546,875
Board of Director
Provisional Purchase Consideration at preliminary fair value:
Issuance of common stock for acquisition (in shares)	3,187,500

Acquisition - Preliminary Analy

Acquisition - Preliminary Analysis (Details) - USD ($)	May 29, 2020	Jun. 30, 2021	Dec. 31, 2020
Assets acquired and liabilities assumed at preliminary fair value
Preliminary goodwill		$ 311,000	$ 311,000
Sports Defense LLC
Provisional Purchase Consideration at preliminary fair value:
Purchase price	$ 375
Consideration paid	375
Assets acquired and liabilities assumed at preliminary fair value
Inventories	21
Accounts payable and accrued expenses	(13)
Net tangible assets acquired	64
Total net assets acquired	64
Consideration paid	375
Preliminary goodwill	311
Sports Defense LLC | Product/Technology Related
Assets acquired and liabilities assumed at preliminary fair value
Intangibles	31
Sports Defense LLC | Marketing-Related
Assets acquired and liabilities assumed at preliminary fair value
Intangibles	8
Sports Defense LLC | Customer Related
Assets acquired and liabilities assumed at preliminary fair value
Intangibles	$ 17

Acquisition - Pro-forma Results

Acquisition - Pro-forma Results (Details) - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2020	Jun. 30, 2021
Acquisition
Revenues, net	$ 348	$ 683
Net loss allocable to common shareholders	$ (1,029)	$ (1,529)
Net loss per share	$ (0.01)	$ (0.01)
Weighted average number of shares outstanding	78,258,316	102,156,565

Leases - Future minimum lease p

Leases - Future minimum lease payments (Details) $ in Thousands	Jun. 30, 2021USD ($)
Future minimum lease payments, excluding expense reimbursements, under noncancelable operating leases
2021 (remainder of year)	$ 104
2022	207
2023	207
2024	207
2025	207
Thereafter	1,428
Total undiscounted operating lease payments	2,360
Less: Imputed interest	(335)
Present value of operating lease liability	$ 2,025
Weighted average remaining lease term	9 years 7 months 6 days
Weighted average discount rate	3.00%

Leases - Supplemental cash flow

Leases - Supplemental cash flows information (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Leases
Operating cash flows from operating lease	$ 109
Change in right-of-use asset/liability due to lease amendments	$ 1,275

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	Apr. 12, 2021	Jun. 30, 2021	Jun. 30, 2020
Leases
Operating Lease, Cost		$ 103	$ 6
Lease extended term	5 years

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory, net
Raw materials	$ 189	$ 190
Work-in-progress	23	22
Finished goods	14	21
Inventory, Gross	226	233
Less: Inventory reserve for excess and slow moving inventory	0	0
Total	$ 226	$ 233

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment	$ 1,217	$ 3,632
Less: accumulated depreciation and amortization	(446)	(3,079)
Property and equipment, net	771	553
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment	$ 940	2,894
Machinery and equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Machinery and equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful Life	10 years
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Property and equipment	$ 49	49
Office furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Office furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful Life	10 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Useful Life	6 years
Property and equipment	$ 228	228
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment	$ 0	$ 461

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Property and Equipment, Net
Depreciation expense	$ 49
Depreciation and amortization expense	$ 56	$ 21

Intangible Assets - Breakdown o

Intangible Assets - Breakdown of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Acquired Finite-Lived Intangible Assets [Line Items]
Total	$ 40	$ 47
Product/Technology Related
Acquired Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets, gross	31	31
Accumulated amortization	(11)	(6)
Total	20	25
Marketing-Related
Acquired Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	(4)	(2)
Total	20	22
Customer Related
Acquired Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets, gross	17	17
Marketing Related - Tradename related intangible asset
Acquired Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets, gross	$ 7	$ 7

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - Technology related and Customer related intangibles - Sports Defense LLC $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Intangibles	$ 55
Expected life	4 years 8 months 12 days
Amortization expense	$ 7

Intangible Assets - Future Amor

Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Intangible Assets
2021 (remainder of year)	$ 7
2022	14
2023	8
2024	3
2025	2
Thereafter	6
Total	$ 40	$ 47

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Accrued Expenses and Other Current Liabilities
Salaries, benefits and incentive compensation	$ 47	$ 43
Other	23	47
Total accrued expenses and other current liabilities	$ 70	$ 90

Common Stock - Additional Infor

Common Stock - Additional Information (Details)	Mar. 31, 2021USD ($)$ / sharesshares	Feb. 10, 2020shares	Nov. 06, 2019USD ($)$ / sharesshares	Sep. 10, 2019USD ($)shareholder$ / sharesshares	Mar. 20, 2020USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / shares	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Aug. 01, 2021shares	Jun. 30, 2021$ / sharesshares	Jun. 22, 2021shares	Jun. 21, 2021shares	Dec. 31, 2020$ / sharesshares	Aug. 02, 2020shares	May 26, 2020shares	May 25, 2020shares	Feb. 09, 2020shares	Aug. 27, 2019$ / shares
Class of Stock [Line Items]
Common stock, par value | $ / shares										$ 0.001			$ 0.001
Aggregate purchase price						$ 285,000	$ 375,000	$ 620,000
Authorized shares of common stock | shares		3,000,000,000							3,000,000,000	750,000,000	750,000,000	3,000,000,000	750,000,000	750,000,000	3,000,000,000	100,000,000	100,000,000
Private placement
Class of Stock [Line Items]
Common stock, par value | $ / shares			$ 0.001	$ 0.001
Issue price per share | $ / shares	$ 0.08		$ 0.014	$ 0.053525	$ 0.04	$ 0.08												$ 0.014
Issuances of common stock, net of issuance costs (in shares) | shares	3,563,000			3,269,500	15,500,000
Cash proceeds			$ 560,000	$ 175,000
Number of shareholders | shareholder				2
Additional shares issued on common stock | shares			39,999,998	9,230,500
Issuance costs			$ 56,000	$ 5,000
Aggregate purchase price	$ 285,000				$ 620,000
Percentage of fee equal to gross proceeds and warrants					6.00%
Percentage of shares issuable to warrant holders based on the number of shares issued to investors					10.00%
Warrants exercisable term					3 years
Exercise price of warrants | $ / shares					$ 0.04
Minimum | Private placement
Class of Stock [Line Items]
Reverse stock split ratio		0.03
Maximum | Private placement
Class of Stock [Line Items]
Value of common stock offered on initial closing date				175,000
Value of common stock offered on subsequent closing date				$ 575,000
Reverse stock split ratio		0.01

Common Stock - Common stock res

Common Stock - Common stock reserved for issuance (Details)	6 Months Ended
	Jun. 30, 2021shares
Common Stock
Share-based compensation plan	17,000,000
Warrants to purchase common Stock	19,827,500

Concentrations of Risk (Details

Concentrations of Risk (Details) - customer	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Concentration Risk [Line Items]
Threshold used for calculating concentration of risk, percentage	10.00%	10.00%
Major Customers | Total Revenue | Customer risk
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	10.00%	10.00%
Number of major customers	3	3
Major Customers | Accounts Receivable | Accounts receivable risk
Concentration Risk [Line Items]
Number of major customers	3	4
Customer One | Total Revenue | Customer risk
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	28.00%	23.00%
Customer One | Accounts Receivable | Accounts receivable risk
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	13.00%	59.00%
Customer Two | Total Revenue | Customer risk
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	24.00%	27.00%
Customer Two | Accounts Receivable | Accounts receivable risk
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	0.00%	13.00%
Customer Three | Total Revenue | Customer risk
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	16.00%	39.00%
Customer Three | Accounts Receivable | Accounts receivable risk
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	44.00%	12.00%
Customer Four | Accounts Receivable | Accounts receivable risk
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	25.00%	11.00%

Share-based Compensation - 2019

Share-based Compensation - 2019 Plan (Details) - 2019 Plan - shares	6 Months Ended
	Jun. 30, 2021	May 03, 2021	May 02, 2021	May 26, 2020	May 25, 2020	Aug. 28, 2019
Share-based Compensation
Common stock reserved for issuance	17,000,000	20,000,000	17,000,000	17,000,000	2,000,000	2,000,000
Awards Issued	14,705,949
Awards Available for Grant	2,294,051

Share-based Compensation - Opti

Share-based Compensation - Option activity (Details) - Incentive stock options - 2019 Plan - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of Options
Outstanding Beginning Balance	13,705,949	1,000,000
Granted	1,666,667	12,705,949
Outstanding Ending Balance	15,372,616	13,705,949	1,000,000
Exercisable at June 30, 2021	9,105,949
Weighted Average Exercise Price
Outstanding Beginning Balance	$ 0.027736	$ 0.053525
Granted	0.08	0.0291
Outstanding Ending Balance	0.034889	$ 0.027736	$ 0.053525
Exercisable at June 30, 2021	$ 0.025441
Weighted Average Contractual Term in Years
Granted	10 years	10 years
Outstanding Balance	8 years 10 months 28 days	9 years 3 months 25 days	9 years 7 months 6 days
Exercisable at June 30, 2021	8 years 9 months

Share-based Compensation - Assu

Share-based Compensation - Assumptions (Details)	6 Months Ended
	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate - Minimum	0.46%
Risk-free interest rate - Maximum	0.86%
Dividend yield	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	171.12%
Expected term	5 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	172.19%
Expected term	5 years 3 months

Share-based Compensation - Rest

Share-based Compensation - Restrictive stock awards (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 08, 2021	Feb. 29, 2020	Feb. 17, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Number of Units
Granted						7,311,904
Exercised and converted to common shares				(1,383,333)		(5,928,571)
Outstanding						1,383,333
Weighted Average Grant Date Fair Value
Granted						$ 0.023
Exercised and converted to common shares				$ 0.060		0.014
Outstanding						$ 0.060
Restricted stock award
Weighted Average Grant Date Fair Value
Value of awards		$ 83
Closing stock price		$ 0.014
Stock-based compensation expense				$ 143	$ 104
Mr. Levy | Restricted stock award
Number of Units
Exercised and converted to common shares	(1,383,333)		(5,928,571)

Share-based Compensation - Warr

Share-based Compensation - Warrants (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of Options
Outstanding at beginning of period	7,367,500	5,250,000
Granted	12,460,000	2,117,500
Outstanding at end of period	19,827,500	7,367,500	5,250,000
Exercisable at end of period	19,827,500
Weighted Average Exercise Price
Outstanding at beginning of period	$ 0.050720	$ 0.014000
Granted	0.135188	0.050720
Outstanding at end of period	$ 0.094078	$ 0.050720	$ 0.014000
Exercisable at end of period	$ 0.094078
Weighted Average Contractual Term in Years
Granted	4 years 9 months 7 days	5 years
Outstanding at December 31,	3 years 4 months 20 days	2 years 6 months 14 days	2 years 9 months 21 days
Exercisable at end of period	3 years 4 months 20 days
Intrinsic value of vested outstanding warrants	$ 561,000

Share-based Compensation - Addi

Share-based Compensation - Additional information (Details)

Mar. 08, 2021$ / sharesshares

Jan. 15, 2021$ / sharesshares

Oct. 10, 2020$ / sharesshares

Feb. 17, 2020USD ($)$ / sharesshares

Jul. 31, 2020individualemployeeshares

Mar. 31, 2021USD ($)

Jun. 30, 2020USD ($)

Mar. 31, 2020USD ($)

Jun. 30, 2021USD ($)$ / sharesshares

Dec. 31, 2020$ / sharesshares

May 03, 2021shares

May 02, 2021shares

May 26, 2020shares

May 25, 2020shares

Aug. 28, 2019shares

Share-based Compensation

Aggregate purchase price | $

$ 285,000

$ 375,000

$ 620,000

Options

Share-based Compensation

Shares awarded

325,000

Vesting percentage

10.00%

2019 Plan

Share-based Compensation

Number of shares reserved for future issuance

17,000,000

20,000,000

17,000,000

17,000,000

2,000,000

2,000,000

Number of shares available for grant

14,705,949

Shares awarded

2,294,051

2019 Plan | Options

Share-based Compensation

Shares awarded

5,000,000

2019 Plan | Executive officer

Share-based Compensation

Number of shares available for grant

500,000

500,000

500,000

2019 Long-Term Incentive Plan | Board of Director

Share-based Compensation

Vesting percentage

25.00%

Aggregate purchase price | $

$ 40,000

2019 Long-Term Incentive Plan | Board of Director | First grant

Share-based Compensation

Vesting percentage

50.00%

Number of options granted

2,857,141

Exercise price per share | $ / shares

$ 0.014

2019 Long-Term Incentive Plan | Board of Director | Vesting in equal installments on June 2020 and September 2020

Share-based Compensation

Vesting percentage

50.00%

Incentive stock options | 2019 Plan

Share-based Compensation

Shares awarded

5,325,000

Number of employees to whom options granted | employee

2

Number of contractors to whom options granted | individual

1

Term of options

10 years

Number of options granted

1,666,667

12,705,949

Exercise price per share | $ / shares

$ 0.08

$ 0.0291

Intrinsic value | $

$ 988,000

Un-recognized share-based compensation expense | $

$ 75,000

Period of recognition of stock based compensation expense

12 months

Incentive stock options | 2019 Plan | Dr. Jerome Zeldis, a member of the board of directors

Share-based Compensation

Exercise price per share | $ / shares

$ 0.06

Incentive stock options | 2019 Plan | Dr. Jerome Zeldis, a member of the board of directors | Maximum

Share-based Compensation

Number of options granted

666,667

Incentive stock options | 2019 Plan | Mr. Steven Glassman, a member of the board of directors

Share-based Compensation

Exercise price per share | $ / shares

$ 0.08

Incentive stock options | 2019 Plan | Mr. Steven Glassman, a member of the board of directors | Maximum

Share-based Compensation

Number of options granted

500,000

Incentive stock options | 2019 Plan | Contractor

Share-based Compensation

Number of options granted

500,000

Exercise price per share | $ / shares

$ 0.06

Incentive stock options | 2019 Plan | First grant | Contractor

Share-based Compensation

Vesting percentage

20.00%

Incentive stock options | 2019 Plan | Vesting in November 2022 | Contractor

Share-based Compensation

Vesting percentage

80.00%

Restricted stock award

Share-based Compensation

Shares awarded

666,667

Exercise price per share | $ / shares

$ 0.06

Un-recognized share-based compensation expense | $

$ 21,000

Period of recognition of stock based compensation expense

6 months

Note Payable (Details)

Note Payable (Details) - USD ($)	May 28, 2020	Apr. 22, 2020	Jun. 30, 2021	Mar. 04, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Loan amount				$ 127,400,000
PPP loan
Debt Instrument [Line Items]
Loan amount		$ 147,300	$ 127,400		$ 147,300
Term of the loan		2 years
Interest rate		1.00%
Deferred period		6 months
Prepayment penalties		$ 0
EIDL loan
Debt Instrument [Line Items]
Loan amount			$ 271,163		$ 266,279
Term of the loan	30 years
Interest rate	3.75%
Borrowing capacity	$ 260,500
Monthly payment	1,270
Loan advance	$ 8,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details)	Mar. 11, 2021USD ($)$ / sharesshares	Dec. 24, 2020USD ($)security$ / sharesshares	Mar. 31, 2021USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jan. 19, 2021USD ($)$ / shares
Short-term Debt [Line Items]
Number of securities purchase agreement entered into by company | security		2
Proceeds received from convertible notes						$ 1,337,000	$ 0
Notes outstanding						510,904
Unamortized balance of beneficial conversion and warrant features						852,288
Unamortized original issue discount						125,260
Unamortized debt issuance costs						$ 191,547
Issuances of common stock, net of issuance costs			$ 285,000	$ 375,000	$ 620,000
Common stock warrants
Short-term Debt [Line Items]
Number of shares called by warrants | shares		312,500
Exercise price of warrants | $ / shares		$ 0.08
Auctus Note
Short-term Debt [Line Items]
Percentage of principal amount paid as placement agent fees (as a percent)	8.00%
Total cash fee paid to placement agent	$ 120,000
Auctus Warrants
Short-term Debt [Line Items]
Threshold beneficial ownership (as a percent)	4.99%
Alere Financial
Short-term Debt [Line Items]
Warrants exercisable term	3 years
Alere Financial | First Auctus Warrant
Short-term Debt [Line Items]
Number of shares called by warrants | shares	654,545
Exercise price of warrants | $ / shares	$ 0.125
Alere Financial | Second Auctus Warrant
Short-term Debt [Line Items]
Number of shares called by warrants | shares	545,455
Exercise price of warrants | $ / shares	$ 0.15
6% Secured Convertible Promissory Note
Short-term Debt [Line Items]
Principal amount of debt		$ 100,000
Interest rate		6.00%
Conversion price (in dollars per share) | $ / shares		$ 0.08
Auctus Note
Short-term Debt [Line Items]
Warrants exercisable term	5 years
Number of warrants issued | shares	2
Proceeds received from convertible notes	$ 1,337,000
Principal amount of debt	$ 1,500,000
Interest rate	12.00%
Number of months interest guaranteed and deemed to be earned in full as of the Issuance Date	12 months
Increase in interest rate if the Company fails to pay any amount when due (as a percent)	$ 180,000
Increase in interest rate if the Company fails to pay any amount when due (as a percent)	16.00%
Prepayment penalty (as a percent)	110.00%
Number of calendar days after which the note may not be paid in whole or in part	180 days
Prepayment period, number of calendar days	180 days
Threshold calendar days to file registration statement	30 days
Threshold beneficial ownership (as a percent)	4.99%
Conversion price (in dollars per share) | $ / shares	$ 0.10
Term of the loan	1 year
Auctus Note | First Auctus Warrant
Short-term Debt [Line Items]
Number of shares called by warrants | shares	6,000,000
Exercise price of warrants | $ / shares	$ 0.125
Auctus Note | Second Auctus Warrant
Short-term Debt [Line Items]
Exercise price of warrants | $ / shares	$ 0.15
Number of warrants issued | shares	5,000,000
Auctus Note | Auctus Warrants
Short-term Debt [Line Items]
Threshold calendar days to file registration statement	30 days
2021 Purchase Agreement [Member] | Secured Convertible Promissory Note
Short-term Debt [Line Items]
Principal amount of debt								$ 15,000
Conversion price (in dollars per share) | $ / shares								$ 0.03

Warrant Liability (Details)

Warrant Liability (Details)

Mar. 11, 2021shares

Feb. 03, 2021shares

Jan. 01, 2021USD ($)$ / sharesshares

Dec. 24, 2020shares

Nov. 08, 2020USD ($)$ / sharesshares

Mar. 18, 2020shares

Nov. 06, 2019shares

Sep. 10, 2019USD ($)$ / sharesshares

Jun. 30, 2021USD ($)$ / sharesYshares

Jun. 30, 2020USD ($)

Jun. 30, 2021USD ($)$ / sharesYshares

Jun. 30, 2020USD ($)

Dec. 31, 2020USD ($)$ / sharesshares

Mar. 20, 2020$ / shares

Dec. 31, 2019shares

Class of Warrant or Right [Line Items]

Warrants Outstanding | shares

19,827,500

19,827,500

7,367,500

5,250,000

Change in fair value of warrant liability | $

$ (2,000)

$ (2,000)

$ (8,000)

$ (4,000)

Warrant Liability

Class of Warrant or Right [Line Items]

Warrants issued | shares

1,460,000

1,805,000

Warrants Outstanding | shares

5,250,000

8,515,000

8,515,000

7,055,000

Warrants Fair value per share

$ 0.08273

$ 0.03616

$ 0.01086

Warrants Fair value | $

130,000

65,000

56,000

245,000

245,000

123,000

Change in fair value of warrant liability | $

$ (8,000)

$ 2,000

Exercise Price | Warrants Issuance On March 11 2021, Expiring on March 11, 2024 | Minimum

Class of Warrant or Right [Line Items]

Warrants Fair value

0.15

0.15

Exercise Price | Warrants Issuance On March 11 2021, Expiring on March 11, 2024 | Maximum

Class of Warrant or Right [Line Items]

Warrants Fair value

0.125

0.125

Exercise Price | Warrants Issuance On February 03, 2021, Expiring on February 3, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

0.08

0.08

Exercise Price | Warrants Issuance on December 24, 2020, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.08

0.08

Exercise Price | Warrants Issuance on March 18, 2020, Expiring on March 18, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.04

0.04

Exercise Price | Warrants Issuance on September 10, 2019, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.014

0.014

Exercise Price | Warrants Issuance on November 6, 2019, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.014

0.014

Exercise Price | Warrants Issuance On June 30, 2021, Expiring on March 11, 2024 | Minimum

Class of Warrant or Right [Line Items]

Warrants Fair value

0.15

0.15

Exercise Price | Warrants Issuance On June 30, 2021, Expiring on March 11, 2024 | Maximum

Class of Warrant or Right [Line Items]

Warrants Fair value

0.125

0.125

Exercise Price | Warrants Issuance On June 30, 2021, Expiring on February 3, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

0.08

0.08

Exercise Price | Warrants Issuance On June 30, 2021, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.08

0.08

Exercise Price | Warrants Issuance On June 30, 2021, Expiring on March 18, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.04

0.04

Exercise Price | Warrants Issuance On June 30, 2021, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.014

0.014

Exercise Price | Warrants Issuance On June 30, 2021, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.014

0.014

Exercise Price | Warrants Issuance on December 31, 2020, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.08

Exercise Price | Warrants Issuance on December 31, 2020, Expiring on March 18, 2023

Class of Warrant or Right [Line Items]

Warrants Fair value

0.04

Exercise Price | Warrants Issuance on December 31, 2020, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.014

Exercise Price | Warrants Issuance on December 31, 2020, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.014

Stock Price | Warrants Issuance On March 11 2021, Expiring on March 11, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

0.10

0.10

Stock Price | Warrants Issuance On February 03, 2021, Expiring on February 3, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

0.08

0.08

Stock Price | Warrants Issuance on December 24, 2020, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.08

0.08

Stock Price | Warrants Issuance on March 18, 2020, Expiring on March 18, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.04

0.04

Stock Price | Warrants Issuance on September 10, 2019, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.014

0.014

Stock Price | Warrants Issuance on November 6, 2019, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.014

0.014

Stock Price | Warrants Issuance On June 30, 2021, Expiring on March 11, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

0.10

0.10

Stock Price | Warrants Issuance On June 30, 2021, Expiring on February 3, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

0.08

0.08

Stock Price | Warrants Issuance On June 30, 2021, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.08

0.08

Stock Price | Warrants Issuance On June 30, 2021, Expiring on March 18, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.04

0.04

Stock Price | Warrants Issuance On June 30, 2021, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.014

0.014

Stock Price | Warrants Issuance On June 30, 2021, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.014

0.014

Stock Price | Warrants Issuance on December 31, 2020, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.08

Stock Price | Warrants Issuance on December 31, 2020, Expiring on March 18, 2023

Class of Warrant or Right [Line Items]

Warrants Fair value

0.04

Stock Price | Warrants Issuance on December 31, 2020, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.014

Stock Price | Warrants Issuance on December 31, 2020, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.014

Interest Rate (annual) | Warrants Issuance On March 11 2021, Expiring on March 11, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

0.17

0.17

Interest Rate (annual) | Warrants Issuance On February 03, 2021, Expiring on February 3, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

0.18

0.18

Interest Rate (annual) | Warrants Issuance on December 24, 2020, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.17

0.17

Interest Rate (annual) | Warrants Issuance on March 18, 2020, Expiring on March 18, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.66

0.66

Interest Rate (annual) | Warrants Issuance on September 10, 2019, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

1.61

1.61

Interest Rate (annual) | Warrants Issuance on November 6, 2019, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

1.60

1.60

Interest Rate (annual) | Warrants Issuance On June 30, 2021, Expiring on March 11, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

0.87

0.87

Interest Rate (annual) | Warrants Issuance On June 30, 2021, Expiring on February 3, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

0.87

0.87

Interest Rate (annual) | Warrants Issuance On June 30, 2021, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.25

0.25

Interest Rate (annual) | Warrants Issuance On June 30, 2021, Expiring on March 18, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.25

0.25

Interest Rate (annual) | Warrants Issuance On June 30, 2021, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.07

0.07

Interest Rate (annual) | Warrants Issuance On June 30, 2021, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.07

0.07

Interest Rate (annual) | Warrants Issuance on December 31, 2020, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.17

Interest Rate (annual) | Warrants Issuance on December 31, 2020, Expiring on March 18, 2023

Class of Warrant or Right [Line Items]

Warrants Fair value

0.13

Interest Rate (annual) | Warrants Issuance on December 31, 2020, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.13

Interest Rate (annual) | Warrants Issuance on December 31, 2020, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

1.13

Volatility (annual) | Warrants Issuance On March 11 2021, Expiring on March 11, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

172.54

172.54

Volatility (annual) | Warrants Issuance On February 03, 2021, Expiring on February 3, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

171.71

171.71

Volatility (annual) | Warrants Issuance on December 24, 2020, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

172.54

172.54

Volatility (annual) | Warrants Issuance on March 18, 2020, Expiring on March 18, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

137.41

137.41

Volatility (annual) | Warrants Issuance on September 10, 2019, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

139.84

139.84

Volatility (annual) | Warrants Issuance on November 6, 2019, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

138.48

138.48

Volatility (annual) | Warrants Issuance On June 30, 2021, Expiring on March 11, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

170.53

170.53

Volatility (annual) | Warrants Issuance On June 30, 2021, Expiring on February 3, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

170.53

170.53

Volatility (annual) | Warrants Issuance On June 30, 2021, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

170.53

170.53

Volatility (annual) | Warrants Issuance On June 30, 2021, Expiring on March 18, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

170.53

170.53

Volatility (annual) | Warrants Issuance On June 30, 2021, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

170.53

170.53

Volatility (annual) | Warrants Issuance On June 30, 2021, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

170.53

170.53

Volatility (annual) | Warrants Issuance on December 31, 2020, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

172.38

Volatility (annual) | Warrants Issuance on December 31, 2020, Expiring on March 18, 2023

Class of Warrant or Right [Line Items]

Warrants Fair value

172.38

Volatility (annual) | Warrants Issuance on December 31, 2020, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

172.38

Volatility (annual) | Warrants Issuance on December 31, 2020, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

172.38

Time to Maturity (Years) | Warrants Issuance On March 11 2021, Expiring on March 11, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value | $

5

5

Time to Maturity (Years) | Warrants Issuance On February 03, 2021, Expiring on February 3, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value | $

3

3

Time to Maturity (Years) | Warrants Issuance on December 24, 2020, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value | $

3

3

Time to Maturity (Years) | Warrants Issuance on March 18, 2020, Expiring on March 18, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value | $

3

3

Time to Maturity (Years) | Warrants Issuance on September 10, 2019, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value | $

3

3

Time to Maturity (Years) | Warrants Issuance on November 6, 2019, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value | $

3

3

Time to Maturity (Years) | Warrants Issuance On June 30, 2021, Expiring on March 11, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value | $

4.70

4.70

Time to Maturity (Years) | Warrants Issuance On June 30, 2021, Expiring on February 3, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value | $

4.70

4.70

Time to Maturity (Years) | Warrants Issuance On June 30, 2021, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value | $

2.60

2.60

Time to Maturity (Years) | Warrants Issuance On June 30, 2021, Expiring on March 18, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value | $

2.48

2.48

Time to Maturity (Years) | Warrants Issuance On June 30, 2021, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value | $

1.72

1.72

Time to Maturity (Years) | Warrants Issuance On June 30, 2021, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value | $

1.20

1.20

Time to Maturity (Years) | Warrants Issuance on December 31, 2020, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value | $

2.98

Time to Maturity (Years) | Warrants Issuance on December 31, 2020, Expiring on March 18, 2023

Class of Warrant or Right [Line Items]

Warrants Fair value | $

2.21

Time to Maturity (Years) | Warrants Issuance on December 31, 2020, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value | $

1.85

Time to Maturity (Years) | Warrants Issuance on December 31, 2020, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value | $

1.69

Calculated fair value per share | Warrants Issuance On March 11 2021, Expiring on March 11, 2024 | Minimum

Class of Warrant or Right [Line Items]

Warrants Fair value

0.0093

0.0093

Calculated fair value per share | Warrants Issuance On March 11 2021, Expiring on March 11, 2024 | Maximum

Class of Warrant or Right [Line Items]

Warrants Fair value

0.0094

0.0094

Calculated fair value per share | Warrants Issuance On February 03, 2021, Expiring on February 3, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

0.0690703

0.0690703

Calculated fair value per share | Warrants Issuance on December 24, 2020, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.0692188

0.0692188

Calculated fair value per share | Warrants Issuance on March 18, 2020, Expiring on March 18, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.0307299

0.0307299

Calculated fair value per share | Warrants Issuance on September 10, 2019, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.01091

0.01091

Calculated fair value per share | Warrants Issuance on November 6, 2019, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.01095

0.01095

Calculated fair value per share | Warrants Issuance On June 30, 2021, Expiring on March 11, 2024 | Minimum

Class of Warrant or Right [Line Items]

Warrants Fair value

0.0093

0.0093

Calculated fair value per share | Warrants Issuance On June 30, 2021, Expiring on March 11, 2024 | Maximum

Class of Warrant or Right [Line Items]

Warrants Fair value

0.0094

0.0094

Calculated fair value per share | Warrants Issuance On June 30, 2021, Expiring on February 3, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

0.0692188

0.0692188

Calculated fair value per share | Warrants Issuance On June 30, 2021, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.0692188

0.0692188

Calculated fair value per share | Warrants Issuance On June 30, 2021, Expiring on March 18, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.0307299

0.0307299

Calculated fair value per share | Warrants Issuance On June 30, 2021, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.01091

0.01091

Calculated fair value per share | Warrants Issuance On June 30, 2021, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.01095

0.01095

Calculated fair value per share | Warrants Issuance on December 31, 2020, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0.0692188

Calculated fair value per share | Warrants Issuance on December 31, 2020, Expiring on March 18, 2023

Class of Warrant or Right [Line Items]

Warrants Fair value

0.0307299

Calculated fair value per share | Warrants Issuance on December 31, 2020, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.01091

Calculated fair value per share | Warrants Issuance on December 31, 2020, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0.01095

Future Estimated Quarterly Dividend per share( | Warrants Issuance On March 11 2021, Expiring on March 11, 2024

Class of Warrant or Right [Line Items]

Warrants Fair value

0

0

Future Estimated Quarterly Dividend per share( | Warrants Issuance on December 24, 2020, Expiring on December 24, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0

0

Future Estimated Quarterly Dividend per share( | Warrants Issuance on March 18, 2020, Expiring on March 18, 2020

Class of Warrant or Right [Line Items]

Warrants Fair value

0

0

Future Estimated Quarterly Dividend per share( | Warrants Issuance on September 10, 2019, Expiring on September 10, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0

0

Future Estimated Quarterly Dividend per share( | Warrants Issuance on November 6, 2019, Expiring on November 6, 2022

Class of Warrant or Right [Line Items]

Warrants Fair value

0

0

Private placement

Class of Warrant or Right [Line Items]

Warrants issued | shares

1,200,000

260,000

255,000

1,550,000

4,000,000

1,250,000

Warrants to purchase shares of common stock | shares

1

1

Warrants Fair value per share

$ 0.04

Private placement | Exercise Price | Minimum

Class of Warrant or Right [Line Items]

Warrants Fair value

0.014

0.014

Private placement | Exercise Price | Maximum

Class of Warrant or Right [Line Items]

Warrants Fair value

0.15

0.15

Private placement | Time to Maturity (Years)

Class of Warrant or Right [Line Items]

Warrants Fair value | Y

3

3

Related Party Transactions (Det

Related Party Transactions (Details)	May 29, 2020shares	Jun. 30, 2021shares	Dec. 31, 2020USD ($)	Dec. 24, 2020USD ($)loan
Sports Defense LLC
Related Party Transaction [Line Items]
Issuance of common stock for acquisition (in shares)	9,375,000
Mr. Stein, a member of the board of directors
Related Party Transaction [Line Items]
Number of secured convertible promissory notes | loan				2
Face amount of debt | $				$ 100,000
Mr. Stein, a member of the board of directors | Sports Defense LLC
Related Party Transaction [Line Items]
Issuance of common stock for acquisition (in shares)		3,187,500
Dr. Jerome Zeldis, a member of the board of directors
Related Party Transaction [Line Items]
Outstanding amount | $			$ 30,000
Adynxx | Mr. Levy | Sports Defense LLC
Related Party Transaction [Line Items]
Issuance of common stock for acquisition (in shares)		1,546,875

Subsequent Events (Details)

Subsequent Events (Details) - shares	Aug. 02, 2021	Jun. 30, 2021	May 03, 2021	May 02, 2021	May 26, 2020	May 25, 2020	Aug. 28, 2019
2019 Plan
Subsequent Events
Common stock reserved for issuance		17,000,000	20,000,000	17,000,000	17,000,000	2,000,000	2,000,000
Subsequent Events
Subsequent Events
Common stock reserved for issuance	3,000,000,000
Subsequent Events | 2019 Plan
Subsequent Events
Common stock reserved for issuance	750,000,000